Skip to main content
THC-olie Wiki

Bronnen

Onze volledige bronnenbibliotheek (1033). Beleid: uitsluitend verifieerbare, bij voorkeur peer-reviewed of gezaghebbend-institutionele bronnen, met werkende URL of DOI. Nooit verzonnen.

  1. (systematische review CIPN RCT's) (2026). Cannabinoids in the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Randomized Controlled Trials. Journal of Pain & Palliative Care Pharmacotherapy. bron
  2. A&O Shearman (analyse arrest C-663/18, Hof van Justitie EU) (2020). CJEU landmark ruling confirms CBD not a narcotic drug and member states may not prohibit marketing. A&O Shearman - Life Sciences Insights. bron
  3. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA (2023). Chemistry and Biological Activities of Cannflavins of the Cannabis Plant. Cannabis and Cannabinoid Research. doi:10.1089/can.2023.0128 bron
  4. Abdelrahman AI, et al. (2024). Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. doi:10.1007/s00228-024-03710-9 bron
  5. Abioye A, Ayodele O, Marinkovic A, Patidar R, Akinwekomi A, Sanyaolu A (2020). Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. Journal of Cannabis Research. doi:10.1186/s42238-020-0016-7 bron
  6. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL (2007). Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study. Clinical Pharmacology & Therapeutics. doi:10.1038/sj.clpt.6100200 bron
  7. Abu-Sawwa R, Stehling C (2023). Cannabidiol (Epidiolex). StatPearls / NCBI Bookshelf. bron
  8. Academie voor de Rechtspraktijk (AvdR) (2025). Inwerkingtreding generiek verbod op designerdrugs. avdr.nl/legalflix. bron
  9. Afshar M, Knapp CM, Nathoo I, et al. (2021). Association between secondhand marijuana smoke and respiratory infections in children. Pediatric Research. doi:10.1038/s41390-021-01641-0 bron
  10. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) (2025). Autorización de importación de estupefacientes y psicotrópicos para uso personal en viajes. aemps.gob.es. bron
  11. Aghaei AM, Spechler PA, Geddes L, et al. (2024). Sex Differences in the Acute Effects of Oral THC: A Randomized, Placebo-Controlled, Crossover Human Laboratory Study. medRxiv (preprint). doi:10.1101/2023.11.29.23299193 bron
  12. Ahmed S, Roth RM, Stanciu CN, Brunette MF (2021). The Impact of THC and CBD in Schizophrenia: A Systematic Review. Frontiers in Psychiatry. doi:10.3389/fpsyt.2021.694394 bron
  13. Ahmed W, Katz S (2018). Therapeutic Use of Cannabis in Inflammatory Bowel Disease. Gastroenterology & Hepatology. bron
  14. Albert Einstein College of Medicine / Montefiore (2023). Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) (NCT03202303). ClinicalTrials.gov. bron
  15. Almog S, Aharon-Peretz J, Vulfsons S, et al. (2020). The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. European Journal of Pain. doi:10.1002/ejp.1605 bron
  16. ALS Centrum Nederland (2023). Cannabis en ALS. ALS Centrum kennisbank. bron
  17. American Academy of Ophthalmology (2018). Why Eye Doctors Don't Recommend Marijuana for Glaucoma (infographic). American Academy of Ophthalmology (aao.org). bron
  18. American Academy of Ophthalmology (Boyd K, Turbert D) (2023). Does Marijuana Help Treat Glaucoma or Other Eye Conditions?. American Academy of Ophthalmology (aao.org). bron
  19. American Academy of Sleep Medicine (Winkelman JW, et al.) (2025). Treatment of restless legs syndrome and periodic limb movement disorder: an AASM clinical practice guideline. Journal of Clinical Sleep Medicine. doi:10.5664/jcsm.11390 bron
  20. American College of Obstetricians and Gynecologists (ACOG) (2025). Cannabis Use During Pregnancy and Lactation (Clinical Consensus No. 10). Obstetrics & Gynecology / ACOG. bron
  21. American College of Obstetricians and Gynecologists (ACOG) (2024). ACOG Clinical Consensus No. 7: The Use of Cannabis Products for the Management of Pain Associated With Gynecologic Conditions. Obstetrics & Gynecology. bron
  22. American Society of Clinical Oncology (ASCO) Expert Panel (2024). Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology. doi:10.1200/JCO.23.02596 bron
  23. American Society of Regional Anesthesia and Pain Medicine (ASRA) (2023). All Patients Should be Screened for Cannabis Use Before Surgery, First U.S. Guidelines Recommend. ASRA News. bron
  24. Amissah RQ, Vogt NA, Chen C, Urban K, Khokhar J (2022). Prevalence and characteristics of cannabis-induced toxicoses in pets: Results from a survey of veterinarians in North America. PLoS ONE 17(4):e0261909. doi:10.1371/journal.pone.0261909 bron
  25. Anderson GD, Chan LN (2016). Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clinical Pharmacokinetics. doi:10.1007/s40262-016-0400-9 bron
  26. Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, Amminger GP, McGregor IS (2021). Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. Journal of Clinical Psychopharmacology. doi:10.1097/JCP.0000000000001427 bron
  27. Andre R, Gomes AP, Pereira-Leite C, et al. (2024). The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review. Pharmaceuticals (Basel). doi:10.3390/ph17111543 bron
  28. Andreis K, et al. (2022). Cannabinoid CB1 receptors regulate salivation. Scientific Reports. doi:10.1038/s41598-022-17987-2 bron
  29. Andries A, Frystyk J, Flyvbjerg A, Støving RK (2014). Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. International Journal of Eating Disorders. doi:10.1002/eat.22173 bron
  30. Anil SM, Peeri H, Koltai H (2022). Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. Frontiers in Pharmacology. doi:10.3389/fphar.2022.908198 bron
  31. Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, Shmueli D, Golan D, Castellanos FX (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism. doi:10.1186/s13229-021-00420-2 bron
  32. ArentFox Schiff LLP (2023). Weed Watching – CBP Immigration Policy Enforcement Relating to Marijuana Use and Industry. afslaw.com. bron
  33. Armour M, Sinclair J, Bouchard G, Noll B, Smith CA (2022). 'Should I Inhale?' — Perceptions, Barriers, and Drivers for Medicinal Cannabis Use amongst Australian Women with Primary Dysmenorrhoea: A Qualitative Study. Journal of Clinical Medicine 11(3):818. doi:10.3390/jcm11030818 bron
  34. Arnold JC et al. (2023). The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clinical and Translational Science. doi:10.1111/cts.13425 bron
  35. Arnold JC, et al. (2025). Distinct Interactions of Cannabinol and Its Cytochrome P450-Generated Metabolites with Receptors and Sensory Neurons. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.5c00938 bron
  36. Ateş G, Welsch P, Klose P, Phillips T, Lambers B, Häuser W, Radbruch L (2026). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, CD012182.pub3. doi:10.1002/14651858.CD012182.pub3 bron
  37. Ateş G, Welsch P, Klose P, Phillips T, Lambers B, Häuser W, Radbruch L (2026). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD012182.pub3 bron
  38. Auteurs niet vermeld in zoekresultaat (2024). Pharmacokinetics and Side Effects of Δ9-Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD. Kidney International Reports. bron
  39. Auteurs Pharmacological Research (zie DOI) (2022). Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms. Pharmacological Research. doi:10.1016/j.phrs.2022.106205 bron
  40. Autoriteit Persoonsgegevens (2025). Checking for use of alcohol, drugs or medicines (in the employment relationship). autoriteitpersoonsgegevens.nl. bron
  41. Autoriteit Persoonsgegevens (2025). Mijn privacy bij ziekte. autoriteitpersoonsgegevens.nl. bron
  42. Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M (2020). Cannabinoids for the treatment of chronic pruritus: A review. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2020.01.036 bron
  43. Aviram J, Samuelly-Leichtag G (2017). Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Physician. bron
  44. AWVN (Algemene Werkgeversvereniging Nederland) (2024). Alcohol-, drugs- en medicijnen (ADM-beleid). awvn.nl. bron
  45. Babayeva M, Loewy ZG. (2023). Cannabis Pharmacogenomics: A Path to Personalized Medicine. Current Issues in Molecular Biology. doi:10.3390/cimb45040228 bron
  46. Badowski ME, et al. (StatPearls) (2023). Dronabinol. StatPearls / NCBI Bookshelf. bron
  47. Bahji A, Chinna Meyyappan A, Hawken ER (2020). Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis. The Canadian Journal of Psychiatry. doi:10.1177/0706743719892717 bron
  48. Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP (2020). Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Network Open. doi:10.1001/jamanetworkopen.2020.2370 bron
  49. Balachandran R, Co M, Turner JW, Turner AJ, Bhatt DL, Harris JA, Bhatt DL (2024). Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Frontiers in Pharmacology. doi:10.3389/fphar.2024.1282831 bron
  50. Bancks MP, Pletcher MJ, Kertesz SG, Sidney S, Rana JS, Schreiner PJ (2015). Marijuana use and risk of prediabetes and diabetes by middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Diabetologia. doi:10.1007/s00125-015-3740-3 bron
  51. Bansal S, et al. (2023). Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.2973 bron
  52. Barakji J, Korang SK, Feinberg J, Maagaard M, Mathiesen O, Gluud C, Jakobsen JC (2023). Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PLOS One. doi:10.1371/journal.pone.0267420 bron
  53. Barnett AG, van der Pols JC, Dobson AJ (2005). Regression to the mean: what it is and how to deal with it. International Journal of Epidemiology. doi:10.1093/ije/dyh299 bron
  54. Barré T, Cazorla G, Di Beo V, Lopez F, Radoszycki L, Maradan G, Baunez C, Carrieri P (2025). Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey. Parkinson's Disease. doi:10.1155/padi/2979089 bron
  55. Barrett ML, Scutt AM, Evans FJ (1986). Cannflavin A and B, prenylated flavones from Cannabis sativa L.. Experientia. doi:10.1007/BF02118655 bron
  56. Barrus DG, Capogrossi KL, Cates SC, et al. (2016). Tasty THC: Promises and Challenges of Cannabis Edibles. Methods Report (RTI Press). bron
  57. Bartkowiak-Wieczorek J, et al. (2023). THC-Reduced Cannabis sativa L.-How Does the Solvent Determine the Bioavailability of Cannabinoids Given Orally?. Nutrients 15(12):2646. doi:10.3390/nu15122646 bron
  58. Bautista JL, Yu S, Tian L (2021). Flavonoids in Cannabis sativa: Biosynthesis, Bioactivities, and Biotechnology. ACS Omega. doi:10.1021/acsomega.1c00318 bron
  59. Bedrocan (2024). Kwaliteitsnormen: GMP en GMCCP. bedrocan.com. bron
  60. Bedrocan (2024). Veelgestelde vragen over medicinale cannabis. bedrocan.com. bron
  61. Bedrocan / Bureau voor Medicinale Cannabis (2024). Aandoeningen — Waar wordt medicinale cannabis bij toegepast?. bedrocan.com / cannabisbureau.nl. bron
  62. Bedrocan BV (2024). Wie zijn er verantwoordelijk voor de levering van medicinale cannabis in Nederland?. bedrocan.com. bron
  63. Bedrocan International (z.j.). Bijwerkingen en risico's van medicinale cannabis. Bedrocan.com. bron
  64. Bedrocan International (2024). Medicinal cannabis varieties and standardisation (THC/CBD-gehalten). bedrocan.com. bron
  65. Bedrocan International (2024). Toediening van medicinale cannabis: wat zijn de opties?. bedrocan.com. bron
  66. Bedrocan International (2026). Medicinale cannabis en de werking. bedrocan.com (zorgverlenersinformatie). bron
  67. Bedrocan International (2023). How oromucosal administration of cannabinoids works. bedrocan.com. bron
  68. Bedrocan International (2024). Vapen versus verdampen: wat is het verschil en wat zijn de risico's. bedrocan.com. bron
  69. Bedrocan International (2023). Bedrocan bij de Keuringsdienst van Waarde over CBD-olie. bedrocan.com. bron
  70. Bedrocan International (2024). Cannabisolie, wietolie of CBD-olie van de apotheek. bedrocan.com. bron
  71. Bedrocan International (2024). Het belang van standaardisatie van medicinale cannabis. bedrocan.com. bron
  72. Bedrocan International (2025). Mediwiet of medicinale cannabis? Officiële medicinale wiet. bedrocan.com. bron
  73. Bedrocan International (2024). Dosering van cannabis bij patienten. bedrocan.com. bron
  74. Bedrocan International B.V. (2024). Wat is CBD?. bedrocan.com. bron
  75. Bedrocan International BV (actueel). Cannabisolie, wietolie of CBD-olie van de apotheek. Bedrocan (officiële GMP-teler voor het Bureau voor Medicinale Cannabis). bron
  76. Beers JL, Fu D, Jackson KD. (2021). Cytochrome P450–Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol. Drug Metabolism and Disposition. bron
  77. Belastingdienst (2026). Voorgeschreven medicijnen - aftrek zorgkosten. belastingdienst.nl. bron
  78. Beletsky A, Liu C, Lochte B, Samuel N, Grant I (2024). Cannabis and Anxiety: A Critical Review. Medical Cannabis and Cannabinoids. doi:10.1159/000534855 bron
  79. Belgische Federale Overheidsdienst Volksgezondheid (2015). Koninklijk Besluit van 11 juni 2015 tot het reglementeren van producten die een of meer tetrahydrocannabinolen bevatten. Belgisch Staatsblad / etaamb.openjustice.be. bron
  80. Bell AD, Bhatt M, Blake A, et al. (2023). Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. Cannabis and Cannabinoid Research. doi:10.1089/can.2021.0156 bron
  81. Bell AD, MacCallum C, Margolese S, et al. (2024). Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review. Pain Management Nursing. doi:10.1016/j.pmn.2023.10.003 bron
  82. Bell, C.; Slim, J.; Flaten, H.K.; Lindberg, G.; Arek, W.; Monte, A.A. (2015). Butane Hash Oil Burns Associated with Marijuana Liberalization in Colorado. Journal of Medical Toxicology. doi:10.1007/s13181-015-0501-0 bron
  83. Belladelli F, Del Giudice F, Kasman A, Kold Jensen T, Jørgensen N, Salonia A, Eisenberg ML (2021). The association between cannabis use and testicular function in men: A systematic review and meta-analysis. Andrology 9(2):503-510. doi:10.1111/andr.12953 bron
  84. Benedict K, et al. (2020). Cannabis Use and Fungal Infections in a Commercially Insured Population, United States, 2016. Emerging Infectious Diseases. doi:10.3201/eid2606.191570 bron
  85. Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology. doi:10.1038/npp.2011.6 bron
  86. Berger G, Arora N, Burkovskiy I, Xia Y, Chinnadurai A, Westhofen R, Hagn G, Cox A, Kelly M, Zhou J, Lehmann C (2019). Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice. Molecules. doi:10.3390/molecules24234239 bron
  87. Beuning C, et al. (2024). Hypothesized pharmacogenomic and medication influences on tetrahydrocannabinol and cannabidiol metabolism in a cohort of unselected oral cannabis users. PMC (NIH/NCBI). bron
  88. Beyer, E. et al. (2024). Brain reward function in people who use cannabis: a systematic review. Frontiers in Behavioral Neuroscience. doi:10.3389/fnbeh.2023.1323609 bron
  89. Bhagavan C, Kung S, Doppen M, John M, Vakalalabure I, Oldfield K, Braithwaite I, Newton-Howes G (2020). Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis. CNS Drugs. doi:10.1007/s40263-020-00773-x bron
  90. Bhaskar A, et al. (red.) (2024). Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions. PMC (peer-reviewed richtlijn). bron
  91. Bhattacharyya S, Egerton A, Kim E, Rosso L, Riano Barros D, Hammers A, Brammer M, Turkheimer FE, Howes OD, McGuire P (2017). Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. Scientific Reports. doi:10.1038/s41598-017-14203-4 bron
  92. Bijwerkingencentrum Lareb (Moeders van Morgen) (z.j.). CBD (cannabidiol) tijdens de zwangerschap. Lareb.nl. bron
  93. Bijwerkingencentrum Lareb & Bureau voor Medicinale Cannabis (2023). Resultaten onderzoek naar patiëntervaringen met medicinale cannabis (cohortstudie 2021-2023). Lareb.nl. bron
  94. Bijwerkingencentrum Lareb & Bureau voor Medicinale Cannabis (z.j.). Onderzoek: Ervaring met medicinale cannabis (cohortstudie). lareb.nl. bron
  95. Bijwerkingencentrum Lareb & Bureau voor Medicinale Cannabis (2020). Uw ervaring met medicinale cannabis (mijnmedcannabis.nl). lareb.nl. bron
  96. Bilbao A, Spanagel R (2022). Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine. doi:10.1186/s12916-022-02459-1 bron
  97. Black N, et al. (2026). The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry. bron
  98. Black N, et al. (2026). The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry. bron
  99. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (2019). Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. The Lancet Psychiatry 6(12):995-1010. doi:10.1016/S2215-0366(19)30401-8 bron
  100. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). doi:10.1093/rheumatology/kei183 bron
  101. Blankman JL, Cravatt BF (2013). Chemical Probes of Endocannabinoid Metabolism. Pharmacological Reviews 65(2):849-871. doi:10.1124/pr.112.006387 bron
  102. Blount BC, Karwowski MP, Shields PG, et al. (2020). Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. New England Journal of Medicine. doi:10.1056/NEJMoa1916433 bron
  103. Boehnke KF, Scott JR, Martel MO, et al. (2024). Substituting Medical Cannabis for Medications Among Patients with Rheumatic Conditions in the United States and Canada. ACR Open Rheumatology. doi:10.1002/acr2.11717 bron
  104. Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M (2018). The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomized placebo controlled trial. Psychopharmacology. doi:10.1007/s00213-018-4885-9 bron
  105. Boland EG, Bennett MI, Allgar V, Boland JW (2020). Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Supportive & Palliative Care. doi:10.1136/bmjspcare-2019-002032 bron
  106. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG (2013). Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. British Journal of Pharmacology. doi:10.1111/bph.12043 bron
  107. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R (2017). Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. doi:10.1001/jama.2017.11909 bron
  108. Bonn-Miller MO, Sisley S, Riggs P, et al. (2021). The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLOS ONE. doi:10.1371/journal.pone.0246990 bron
  109. Bottorff JL, Bissell LJL, Balneaves LG, et al. (2013). Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduction Journal. doi:10.1186/1477-7517-10-2 bron
  110. Bowen LL, et al. (2023). Cannabis use for menopause in women aged 35 and over: a cross-sectional survey on usage patterns and perceptions in Alberta, Canada. Menopause (PMC). bron
  111. Boylan PM, et al. (2024). Cannabinoids for obstructive sleep apnea: A systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. doi:10.1002/phar.4622 bron
  112. Braune T, Liu B, et al. (2021). Secondhand marijuana exposure in a convenience sample of young children in New York City. Pediatric Research. doi:10.1038/s41390-020-0958-7 bron
  113. Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y (1996). The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. International Journal of Clinical Pharmacology and Therapeutics. bron
  114. Breuer & Intraval (in opdracht van WODC) (2024). Coffeeshops in Nederland 2024. open.overheid.nl / WODC. bron
  115. Breuer & Intraval / WODC (2025). Coffeeshops in Nederland 2024. WODC / Rijksoverheid. bron
  116. Brown GW, Bellnier TJ, Janda M, Miskowitz K (2021). Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. Journal of the American Pharmacists Association 61(1):e57-e60. doi:10.1016/j.japh.2020.07.028 bron
  117. Brown JD, Winterstein AG (2020). Drug interactions with cannabinoids. CMAJ. doi:10.1503/cmaj.191097 bron
  118. Bui QM, Simpson S, Nordstrom K (2015). Psychiatric and Medical Management of Marijuana Intoxication in the Emergency Department. Western Journal of Emergency Medicine. bron
  119. Bundesamt fuer Gesundheit (BAG) (2024). Addiction and health: Cannabis. Swiss Federal Office of Public Health. bron
  120. Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM) (2024). Medizinisches Cannabis. BfArM, Bundesopiumstelle. bron
  121. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bundesopiumstelle (2024). Travelling with narcotic drugs (Article 75 Schengen certificate). bfarm.de. bron
  122. Bureau voor Medicinale Cannabis (2026). Actueel: prijswijzigingen, etiketten en beleidsregel opiumwetontheffingen; patienteninformatie producten. cannabisbureau.nl. bron
  123. Bureau voor Medicinale Cannabis (2026). Cannabisolie. cannabisbureau.nl (Rijksoverheid). bron
  124. Bureau voor Medicinale Cannabis (2026). Producten - medicinale cannabis (Bedrocan, Bedrobinol, Bediol, Bedica, Bedrolite). cannabisbureau.nl (Rijksoverheid). bron
  125. Bureau voor Medicinale Cannabis (BMC) (2026). Import en export. cannabisbureau.nl. bron
  126. Bureau voor Medicinale Cannabis (BMC) en Bijwerkingencentrum Lareb (2023). Resultaten onderzoek naar patientervaringen met medicinale cannabis. Rijksoverheid / cannabisbureau.nl. bron
  127. Bureau voor Medicinale Cannabis (BMC), CIBG / Ministerie van VWS (actueel). Medicinale cannabis — informatie voor patiënten en zorgverleners. Rijksoverheid (cannabisbureau.nl). bron
  128. Bureau voor Medicinale Cannabis (BMC), Ministerie van VWS (2025). Medicinale cannabis mee op reis. cannabisbureau.nl - Patienteninformatie. bron
  129. Bureau voor Medicinale Cannabis (CIBG, Ministerie van VWS) (z.j.). Patiënteninformatie: werkzaamheid van medicinale cannabis. cannabisbureau.nl. bron
  130. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2024). Office of Medicinal Cannabis – medicinal cannabis indications. Rijksoverheid / cannabisbureau.nl. bron
  131. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2021). Medicinale cannabis, informatiebrochure voor patienten. cannabisbureau.nl. bron
  132. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2021). Medicinale cannabis: informatie voor apothekers en medische beroepsbeoefenaren (versie november 2021). cannabisbureau.nl. bron
  133. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2018). Medicinale cannabis: informatiebrochure voor patienten. cannabisbureau.nl / Rijksoverheid. bron
  134. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2024). Grounds for use. cannabisbureau.nl. bron
  135. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2026). Kwaliteit. cannabisbureau.nl. bron
  136. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2024). Quality of medicinal cannabis. cannabisbureau.nl. bron
  137. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2024). Vernevelaar - Patienteninformatie. cannabisbureau.nl. bron
  138. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2026). Opiumwet. cannabisbureau.nl. bron
  139. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2021). Medicinal Cannabis Information brochure for patients. cannabisbureau.nl. bron
  140. Bureau voor Medicinale Cannabis (Ministerie van VWS) (2024). Specificaties en analysevoorschriften. cannabisbureau.nl. bron
  141. Bureau voor Medicinale Cannabis (Office of Medicinal Cannabis) (2024). Types of medicinal cannabis. Rijksoverheid / Office of Medicinal Cannabis. bron
  142. Bureau voor Medicinale Cannabis (Rijksoverheid) (2024). Medicinale cannabis - informatie voor patiënten en artsen. cannabisbureau.nl. bron
  143. Business Insider Nederland (2023). Overlijdensrisicoverzekering en drugs: wel of geen uitkering?. businessinsider.nl. bron
  144. Busse FP, Fiedler GM, Leichtle A, Hentschel H, Stumvoll M (2008). Lead poisoning due to adulterated marijuana in Leipzig. Deutsches Ärzteblatt International. doi:10.3238/arztebl.2008.0757 bron
  145. Cafaro A, Pigliasco F, Barco S, Negro I, Piccotti E, Manfredini L, Mahameed S, Bandettini R, Debbia C, Mattioli F, Cangemi G (2025). Accidental cannabis intoxication in two young children: clinical presentation and toxicokinetics — a case series. Frontiers in Pharmacology 2025;16:1695194. doi:10.3389/fphar.2025.1695194 bron
  146. CAK (2026). Medicijnen mee op reis (medicijnverklaring). Het CAK. bron
  147. CAK (Centraal Administratie Kantoor) (2024). Schengenverklaring aanvragen — medicijnen mee op reis. hetcak.nl. bron
  148. CAK (Centraal Administratie Kantoor) (2025). Hoe kom ik aan een medicijnverklaring?. hetcak.nl - Medicijnen mee op reis. bron
  149. CAK (Centraal Administratie Kantoor) (2025). Hoe reis ik met medicijnen buiten Europa?. hetcak.nl - Medicijnen mee op reis. bron
  150. CAK (Centraal Administratie Kantoor) (2025). Hoe lang is een medicijnverklaring geldig?. hetcak.nl - Medicijnen mee op reis. bron
  151. CAK (Centraal Administratie Kantoor) (2026). Medicijnen mee op reis. hetcak.nl. bron
  152. CAK (Centraal Administratie Kantoor) (2025). Hoe reis ik met medicijnen binnen Europa?. hetcak.nl - Medicijnen mee op reis. bron
  153. Cambraia Pereira G, et al. (2021). High frequency of spin bias in controlled trials of cannabis derivatives and their synthetic analogues: A meta-epidemiologic study. Journal of Clinical Epidemiology. doi:10.1016/j.jclinepi.2021.08.024 bron
  154. Campana MD, de Paolis G, Sammartino G, Bucci P, Aliberti A, Gasparro R (2025). Cannabinoids: Therapeutic Perspectives for Management of Orofacial Pain, Oral Inflammation and Bone Healing — A Systematic Review. International Journal of Molecular Sciences 26(8):3766. doi:10.3390/ijms26083766 bron
  155. Campello de Oliveira M, Capelo Vides M, Silva Lassi DL, et al. (2023). Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review. Brain Sciences. doi:10.3390/brainsci13070990 bron
  156. Canada Border Services Agency (CBSA) (2024). Travellers: Cannabis at the border. cbsa-asfc.gc.ca. bron
  157. Canada Border Services Agency (CBSA) (2021). Travellers: Penalties for cannabis-related offences. cbsa-asfc.gc.ca. bron
  158. Canadian ADHD Resource Alliance (CADDRA) (2024). Cannabis and ADHD: A CADDRA Position Statement. CADDRA. bron
  159. Cancer Research UK (2022). Cannabis, cannabinoids and cancer – the evidence so far. Cancer Research UK news. bron
  160. Cannabis for Thailand Editorial (2026). What Changed? Thailand Cannabis Law Updates 2026. cannabisforthailand.com. bron
  161. Cannabis Regulations (2026). Is Weed Legal in Japan? 2026 Cannabis Laws & Penalties. cannabisregulations.ai. bron
  162. Cannabis Regulations (redactie) (2026). Is Weed Legal in Spain? 2026 Cannabis Laws & Social Clubs. cannabisregulations.ai. bron
  163. CannabisIndustrie (redactie) (2024). Geen Amsterdam-Oost in wietproef, maar ook geen 'pauze' van PVV. CannabisIndustrie.nl. bron
  164. Cannabisindustrie.nl (2025). Bedrocan reageert op einde monopolie levering aan BMC; wijziging Opiumwet in 2027 van kracht. cannabisindustrie.nl. bron
  165. Cannabisindustrie.nl (redactie) (2026). HHC sinds 28 januari 2026 op Lijst I Opiumwet. cannabisindustrie.nl. bron
  166. CannaInsider (redactie) (2025). Is Marijuana Legal in Spain? What Tourists Should Know in 2025. cannainsider.com. bron
  167. Cappelleti Beneti Branco L, Borja De Oliveira I, Alves GAM, Teranishi M, Xavier D, Sávio Schneider Motta E, Wagner F, Geremias ML, de Vasconcelos AV, Gonçalves Tames Zambrana AC, De Aquino JP (2025). Efficacy and Safety of Cannabidiol Cannabis Extracts for Children and Adolescents with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. European Psychiatry. doi:10.1192/j.eurpsy.2025.369 bron
  168. Cardenas-Rodriguez N, Ignacio-Mejia I, Correa-Basurto J, Carrasco-Vargas H, Vargas-Hernandez MA, Albores-Mendez EM, Mayen-Quinto RD, De La Paz-Valente R, Bandala C (2024). Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition. International Journal of Molecular Sciences. doi:10.3390/ijms25073805 bron
  169. Carley DW, Prasad B, Reid KJ, Malkani R, Attarian H, Abbott SM, et al. (2018). Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. Sleep. doi:10.1093/sleep/zsx184 bron
  170. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2009.00515.x bron
  171. Cascorbi I, Haber M, Werk AN (2023). Clinical Pharmacology of Cannabinoid Therapeutics: Drug Interactions and Side Effects. Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.3037 bron
  172. Cavazos-Rehg PA, Krauss MJ, Cahn E, et al. (2019). Marijuana Promotion Online: An Investigation of Dispensary Practices. Prevention Science 20(2):280-290. doi:10.1007/s11121-018-0889-2 bron
  173. Cawkwell PB, Hong DS, Leikauf JE (2021). Neurodevelopmental Effects of Cannabis Use in Adolescents and Emerging Adults with ADHD: A Systematic Review. Harvard Review of Psychiatry. doi:10.1097/HRP.0000000000000303 bron
  174. CBA Apotheek (2025). Specialist in medicinale cannabis. cba-apotheek.nl. bron
  175. CBA Apotheek (2024). Autorijden met medicinale cannabis en de wet. cba-apotheek.nl. bron
  176. CBC News (2022). B.C. man faces lifetime ban from entering U.S. after border agents find forgotten bottle of CBD oil in his car. cbc.ca. bron
  177. Centers for Disease Control and Prevention (2021). Increases in Availability of Cannabis Products Containing Delta-8 THC and Reported Cases of Adverse Events (HAN 00451). CDC Health Alert Network. bron
  178. Centers for Disease Control and Prevention (CDC) (2020). Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products. CDC (gearchiveerd). bron
  179. Centraal Beheer (2024). Roken en uw overlijdensrisicoverzekering. centraalbeheer.nl. bron
  180. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2024). Rijden met medicinale drugs. cbr.nl. bron
  181. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2024). Rijden onder invloed van drugs: dit zijn de gevolgen. cbr.nl. bron
  182. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2024). Drugs in het verkeer – Rijbewijs kwijt door drugsgebruik. CBR.nl. bron
  183. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2023). Cursus over drugs en verkeer (EMD) – Educatieve Maatregel Drugs. CBR.nl. bron
  184. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2024). Onderzoek naar uw drugsgebruik – Alles wat u wilt weten. CBR.nl. bron
  185. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2024). Rijden met medicinale drugs. CBR.nl. bron
  186. Centraal Bureau Rijvaardigheidsbewijzen (CBR) (2024). Code 95 voor beroepschauffeurs. CBR.nl. bron
  187. Central Narcotics Bureau (CNB) (2025). Singapore's anti-drug laws on Cannabis. Central Narcotics Bureau, Government of Singapore. bron
  188. Centrum voor Criminaliteitspreventie en Veiligheid (CCV) (2024). Coffeeshopbeleid in Nederland. hetccv.nl. bron
  189. Chambers and Partners (2025). Illegal Drugs in Dubai: How to Stay Safe and Legal in the UAE. Chambers and Partners. bron
  190. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, Freeman TP, McGuire P (2020). Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45(11):1799-1806. doi:10.1038/s41386-020-0667-2 bron
  191. Chesney E, Siskind D, Obuobi-Donkor G, et al. (2024). Psychosis associated with cannabis withdrawal: systematic review and case series. The British Journal of Psychiatry. doi:10.1192/bjp.2024.189 bron
  192. Chihuri S, Li G, Chen Q (2017). Interaction of marijuana and alcohol on fatal motor vehicle crash risk: a case-control study. Injury Epidemiology. doi:10.1186/s40621-017-0105-z bron
  193. Childs E, Lutz JA, de Wit H (2017). Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2017.04.030 bron
  194. Childs E, Lutz JA, de Wit H (2017). Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2017.03.030 bron
  195. Chisini LA, Cademartori MG, Francia A, Mederos M, Grazioli G, Conde MCM, Correa MB (2019). Is the use of Cannabis associated with periodontitis? A systematic review and meta-analysis. Journal of Periodontal Research. doi:10.1111/jre.12639 bron
  196. Choi YS, Cho HY, Cho HJ, Jeong SH, Kim KH, Jeong TC, Shin HS (2006). Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Archives of Pharmacal Research. doi:10.1007/BF02977903 bron
  197. Chou R, et al. (Pacific Northwest EPC) (2025). Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2025 Update. AHRQ Comparative Effectiveness Reviews / NCBI Bookshelf. bron
  198. Christensen C, Rose M, Cornett C, Allesoe A (2023). Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn't. Biomedicines. doi:10.3390/biomedicines11082323 bron
  199. Cleveland Clinic (2024). Cannabinoid Hyperemesis Syndrome (CHS). Cleveland Clinic - Health Library. bron
  200. Clinical Cannabis Care (2025). Bijsluiter Medicinale Cannabisolie (versie 4.0). cannabiszorg.nl. bron
  201. Clinical Cannabis Care BV (Cannabiszorg) (2025). Medicinale cannabisolie. cannabiszorg.nl. bron
  202. ClinicalTrials.gov (registry record NCT04520685) (2024). CASCADE: CAnnabidiol Study in Children With Autism Spectrum DisordEr. ClinicalTrials.gov. bron
  203. Clonan E, Shah P, Cloidt M, Laniado N (2025). Frequent recreational cannabis use and its association with caries and severe tooth loss: Findings from the National Health and Nutrition Examination Survey, 2015-2018. Journal of the American Dental Association. doi:10.1016/j.adaj.2024.10.005 bron
  204. CMS Legal (2025). Cannabis law and legislation in the Czech Republic. CMS Expert Guide to a Legal Roadmap to Cannabis. bron
  205. CNX Therapeutics / electronic Medicines Compendium (2024). Sativex Oromucosal Spray - Summary of Product Characteristics. electronic Medicines Compendium (emc). bron
  206. Coelho CF, et al. (2024). The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials. Life (Basel). doi:10.3390/life14111373 bron
  207. Cohen G, Jakus J, Rabinovitz H, Shalev-Antsel S, Almog S, Silber AM, et al. (2023). Development of an Effective Acne Treatment Based on CBD and Herbal Extracts: Preliminary In Vitro, Ex Vivo, and Clinical Evaluation. Evidence-Based Complementary and Alternative Medicine. doi:10.1155/2023/4474255 bron
  208. Cohen LM, Forester BP, Rosenberg PB, et al. (2025). A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease. The American Journal of Geriatric Psychiatry. doi:10.1016/j.jagp.2025.05.006 bron
  209. Colizzi M, Bhattacharyya S (2018). Cannabis use and the development of tolerance: a systematic review of human evidence. Neuroscience & Biobehavioral Reviews. doi:10.1016/j.neubiorev.2018.07.014 bron
  210. College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2024). Cannabis. CBG-MEB.nl. bron
  211. College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2012). Sativex, spray voor oromucosaal gebruik (RVG 111277). Geneesmiddeleninformatiebank. bron
  212. Colucci P, Seng Yue C, Ducharme MP, Benvenga S (2013). A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism. European Endocrinology. bron
  213. Congressional Research Service (CRS) (actueel). Changes to the Statutory Definition of Hemp and Issues for Congress (IF13136). Congressional Research Service, U.S. Congress. bron
  214. Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD (2022). Clinical management of cannabis withdrawal. Addiction. doi:10.1111/add.15743 bron
  215. Consroe P, Laguna J, Allender J, et al. (1991). Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacology Biochemistry and Behavior. doi:10.1016/0091-3057(91)90386-G bron
  216. Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P (2017). Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. European Neuropsychopharmacology. doi:10.1016/j.euroneuro.2017.05.005 bron
  217. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M (2018). Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. doi:10.1038/s41386-018-0011-2 bron
  218. Corsi DJ, Murphy MSQ, Cook J (2021). The Effects of Cannabis on Female Reproductive Health Across the Life Course. Cannabis and Cannabinoid Research 6(4):275-287. doi:10.1089/can.2020.0065 bron
  219. Court of Justice of the European Union (samenvatting via Covington, Inside EU Life Sciences) (2020). CJEU confirms that CBD is not a narcotic drug (zaak C-663/18, 'Kanavape'). Inside EU Life Sciences (Covington). bron
  220. Craft RM, Marusich JA, Wiley JL (2013). Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?. Life Sciences. doi:10.1016/j.lfs.2012.06.009 bron
  221. Crippa JAS, Derenusson GN, Ferrari TB, et al. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology. doi:10.1177/0269881110379283 bron
  222. Crocq MA (2020). History of cannabis and the endocannabinoid system. Dialogues in Clinical Neuroscience. doi:10.31887/DCNS.2020.22.3/mcrocq bron
  223. Curtis A, Mitchell I, Patel S, Ives N, Rickards H (2009). A pilot study using nabilone for symptomatic treatment in Huntington's disease. Movement Disorders. doi:10.1002/mds.22809 bron
  224. Cuttler C, Spradlin A, Cleveland MJ, Craft RM (2020). Short- and Long-Term Effects of Cannabis on Headache and Migraine. The Journal of Pain. doi:10.1016/j.jpain.2019.11.001 bron
  225. Cuttler C, Spradlin A, Nusbaum AT et al. (2018). A naturalistic examination of the perceived effects of cannabis on negative affect. Journal of Affective Disorders. bron
  226. Cuttler C, Stueber A, Cooper ZD, Russo E (2024). Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. doi:10.1038/s41598-024-66879-0 bron
  227. D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, et al. (2016). Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. doi:10.1016/j.bpsc.2015.09.008 bron
  228. Dahlgren MK, El-Abboud C, Lambros AM, Sagar KA, Smith RT, Gruber SA (2022). A survey of medical cannabis use during perimenopause and postmenopause. Menopause. doi:10.1097/GME.0000000000002018 bron
  229. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH (2024). The Clinical Translation of α-humulene – A Scoping Review. Planta Medica. doi:10.1055/a-2307-8183 bron
  230. Damkier P, Lassen D, Christensen MMH, et al. (2019). Interaction between warfarin and cannabis. Basic & Clinical Pharmacology & Toxicology. doi:10.1111/bcpt.13152 bron
  231. Darweesh RS, Khamis TN, El-Elimat T (2020). The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. Naunyn-Schmiedeberg's Archives of Pharmacology 393(10):1871-1886. doi:10.1007/s00210-020-01878-2 bron
  232. de Hoop B, Heerdink ER, Hazekamp A (2018). Medicinal Cannabis on Prescription in The Netherlands: Statistics for 2003-2016. Cannabis and Cannabinoid Research. doi:10.1089/can.2017.0059 bron
  233. De Hoop Leven (2024). Overlijdensrisicoverzekering bij verslavingen. dehoopleven.nl. bron
  234. de Meijer EPM, Bagatta M, Carboni A, et al. (2003). The inheritance of chemical phenotype in Cannabis sativa L.. Genetics. doi:10.1093/genetics/163.1.335 bron
  235. De Morais ER, et al. (2023). Open-label: the clinical effects of adding cannabidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder. European Psychiatry. doi:10.1192/j.eurpsy.2023.524 bron
  236. Dean L, Kane M. (2020). Dronabinol Therapy and CYP2C9 Genotype. Medical Genetics Summaries. NCBI Bookshelf (NIH/NCBI). bron
  237. Decuyper II, Van Gasse AL, Cop N, Sabato V, Faber MA, Mertens C, Bridts CH, Hagendorens MM, De Clerck L, Rihs HP, Ebo DG (2017). Cannabis sativa allergy: looking through the fog. Allergy. doi:10.1111/all.13043 bron
  238. Deng H, Li W (red.) (2025). FAAH and MAGL inhibition: Evolving approaches for endocannabinoid system modulation. Pharmacology & Therapeutics / ScienceDirect. bron
  239. Devinsky O, Cross JH, Laux L, et al. (Cannabidiol in Dravet Syndrome Study Group) (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. doi:10.1056/NEJMoa1611618 bron
  240. Devinsky O, Patel AD, Cross JH, et al. (2018). Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine. doi:10.1056/NEJMoa1714631 bron
  241. Dhamija D, Bello AO, Khan AA, Gutlapalli SD, Sohail M, Patel PA, Midha S, Shukla S, Mohammed L (2023). Evaluation of Efficacy of Cannabis Use in Patients With Attention Deficit Hyperactivity Disorder: A Systematic Review. Cureus. doi:10.7759/cureus.40969 bron
  242. Di Forti M, Quattrone D, Freeman TP, et al. (EU-GEI) (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry. doi:10.1016/S2215-0366(19)30048-3 bron
  243. Diaz-Sanchez ?? / Mahabir VK, et al. (2022). The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials. Pharmaceuticals (Basel). doi:10.3390/ph15010100 bron
  244. Didik SA, et al. (2024). The effects of cannabinoids on the kidney. Acta Physiologica. doi:10.1111/apha.14247 bron
  245. Dierenkliniek Overhage, Cuijk (2023). Marihuana intoxicatie bij de hond en kat. Dierenkliniek Overhage. bron
  246. Doohan PT, Oldfield LD, Arnold JC, et al. (2023). Phytochemical Comparison of Medicinal Cannabis Extracts and Study of Their CYP-Mediated Interactions with Coumarinic Oral Anticoagulants. Medical Cannabis and Cannabinoids. doi:10.1159/000529229 bron
  247. Dopingautoriteit (2026). S8. Cannabinoïden. dopingautoriteit.nl. bron
  248. Dopingautoriteit (2013). WADA verhoogt grenswaarde cannabis. dopingautoriteit.nl. bron
  249. Douane (Belastingdienst) (2024). De Opiumwet - Handboek VGEM. kennisbank.douane.nl. bron
  250. Dowell D, Ragan KR, Jones CM, et al. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recommendations and Reports. bron
  251. Downey LA, King R, Papafotiou K, et al. (2013). The effects of cannabis and alcohol on simulated driving: Influences of dose and experience. Accident Analysis & Prevention. doi:10.1016/j.aap.2012.07.016 bron
  252. DRUGSinfo.nl (2024). Hasj en wiet: de wet. DRUGSinfo.nl. bron
  253. Dutch Natural Healing (2024). Hennepzaadolie vs CBD-olie: de verschillen. dutchnaturalhealing.com. bron
  254. Duval C, et al. (2025). Cannabis impacts female fertility as evidenced by an in vitro investigation and a case-control study. Nature Communications. doi:10.1038/s41467-025-63011-2 bron
  255. Dyal JW, et al. (2023). Current State of Knowledge on Medical Cannabis Use and Risk for Infections: A Practical Guide for Clinicians. Clinical Infectious Diseases. doi:10.1093/cid/ciag343 bron
  256. Eadie L et al. (2024). Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. Journal of Gastroenterology and Hepatology. doi:10.1111/jgh.16730 bron
  257. Eagleston LRM, Kalani NK, Patel RR, et al. (red.) / MDPI (2023). Cannabinoids and Their Receptors in Skin Diseases. International Journal of Molecular Sciences. doi:10.3390/ijms242216523 bron
  258. Eapen V, et al. (2025). Medicinal cannabis for tics in adolescents with Tourette syndrome (open-label feasibility study). BJPsych Open. doi:10.1192/bjo.2025.35 bron
  259. Ebo DG, Van Gasse AL, Decuyper II, et al. (2024). IgE-Mediated Cannabis Allergy and Cross-Reactivity Syndromes: A Roadmap for Correct Diagnosis and Management. Current Allergy and Asthma Reports. doi:10.1007/s11882-024-01159-5 bron
  260. Eerste Kamer der Staten-Generaal (2025). Tegengaan productie van en handel in nieuwe psychoactieve stoffen (wetsvoorstel 36.159) - toevoeging Lijst IA aan de Opiumwet. Eerste Kamer der Staten-Generaal. bron
  261. Eerste Kamer der Staten-Generaal (2024). Toevoeging elfde gemeente (Amsterdam-Oost) aan het experiment gesloten coffeeshopketen (36.279). Eerste Kamer / Staten-Generaal. bron
  262. Eerste Kamer der Staten-Generaal (2011). Plaatsing hasjiesj en hennep met THC van 15 procent of meer op lijst I van de Opiumwet (33.593). eerstekamer.nl. bron
  263. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2022). Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA Journal. doi:10.2903/j.efsa.2022.7322 bron
  264. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2026). Update of the statement on safety of cannabidiol as a novel food / Provisional safe level for cannabidiol. EFSA Journal & EFSA news. doi:10.2903/j.efsa.2026.9862 bron
  265. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2025). Safety of synthetic cannabidiol as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal. doi:10.2903/j.efsa.2025.9527 bron
  266. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2026). Update of the statement on safety of cannabidiol as a novel food. EFSA Journal. doi:10.2903/j.efsa.2026.9862 bron
  267. Ehrenkranz J, Levine MA (2019). Bones and Joints: The Effects of Cannabinoids on the Skeleton. The Journal of Clinical Endocrinology & Metabolism 104(10):4683-4694. doi:10.1210/jc.2019-00665 bron
  268. Eichhorn D, Schaper A, Iwersen-Bergmann S, Ondruschka B, Weber-Papen S, Bernhard M (2025). Cannabis-Associated Emergencies in the Emergency Department. Deutsches Ärzteblatt International 2025; 122: 467–471. doi:10.3238/arztebl.m2025.0074 bron
  269. Elliott J, DeJean D, Clifford T, et al. (2019). Cannabis-based products for pediatric epilepsy: A systematic review. Epilepsia. doi:10.1111/epi.14608 bron
  270. ElSohly MA, Stanford DF, Harland EC, Hikal AH, Walker LA, Little TL Jr, Rider JN, Jones AB (1991). Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. Journal of Pharmaceutical Sciences. bron
  271. EMCDDA (2025). CBD (cannabidiol) - keyword overview. emcdda.europa.eu. bron
  272. EMCDDA (2020). Low-THC cannabis products in Europe. Publications Office of the EU / EMCDDA. bron
  273. Engels FK, de Jong FA, Mathijssen RHJ, Erkens JA, Herings RMC, Verweij J (2007). Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel. The Oncologist 12(3):291-300. doi:10.1634/theoncologist.12-3-291 bron
  274. Englund A, Morrison PD, Nottage J, et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology. doi:10.1177/0269881112460109 bron
  275. Englund A, Morrison PD, Nottage J, et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology. bron
  276. EpilepsieNL (2024). Cannabidiol, CBD-olie, medicinale cannabis. epilepsie.nl. bron
  277. EpilepsieNL (2025). Epidyolex nu ook vergoed voor Tubereuze Sclerose. epilepsie.nl. bron
  278. Erasmus MC Foundation (2023). Klinische studie naar effect van CBD op hersentumoren van start in Erasmus MC. Erasmus MC Foundation nieuwsbericht. bron
  279. Erfocentrum / Bijwerkingencentrum Lareb (z.j.). Cannabis en kinderwens. Zwangerwijzer.nl. bron
  280. Erridge S, Mangal N, Salazar O, Pacchetti B, Sodergren MH (2020). Cannflavins – From plant to patient: A scoping review. Fitoterapia. doi:10.1016/j.fitote.2020.104712 bron
  281. et al. (2024). The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review. Frontiers in Pharmacology. doi:10.3389/fphar.2024.1411631 bron
  282. et al. (2025). Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. Sleep Medicine Reviews (PubMed). bron
  283. et al. (2024). Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Frontiers in Pharmacology. doi:10.3389/fphar.2024.1282831 bron
  284. European Food Safety Authority (EFSA) (2026). Provisional safe level for cannabidiol as a novel food. EFSA News. bron
  285. European Medicines Agency (2019). Epidyolex (cannabidiol) - EPAR medicine overview. European Medicines Agency. bron
  286. European Medicines Agency / GW Pharma (2024). Epidyolex (cannabidiol) - Samenvatting van de productkenmerken (EPAR). European Medicines Agency. bron
  287. European Union Drugs Agency (EUDA, voorheen EMCDDA) (2024). Synthetic cannabinoids and 'Spice' drug profile. euda.europa.eu. bron
  288. European Union Drugs Agency (EUDA, voorheen EMCDDA) (2020). Low-THC cannabis products in Europe. EUDA / Publications Office of the European Union. bron
  289. European Union Drugs Agency (EUDA/EMCDDA) (2023). Cannabis laws in Europe: questions and answers for policymaking. euda.europa.eu. bron
  290. Europese Archives of Psychiatry and Clinical Neuroscience (systematische review en meta-analyse) (2026). Cannabidiol for the treatment of positive and negative symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. doi:10.1007/s00406-026-02249-3 bron
  291. Europese Commissie (2022). Verordening (EU) 2022/1393 tot vaststelling van maximumgehalten aan delta-9-THC in hennepzaden en daarvan afgeleide producten. Publicatieblad van de EU / EUR-Lex. bron
  292. Europese Commissie (DG Landbouw en Plattelandsontwikkeling) (actueel). Hemp. European Commission — agriculture.ec.europa.eu. bron
  293. Evans L, Erridge S, Varadpande M, Aggarwal A, Cowley I, Clarke E, McLachlan K, Coomber R, Rucker JJ, Platt M, Sodergren MH (2025). UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Complex Regional Pain Syndrome. Brain and Behavior. doi:10.1002/brb3.70823 bron
  294. Eyal AM, Berneman-Zeitouni D, Tal D, Schlesinger D, Davidson EM, Raz N (2023). Vapor Pressure, Vaping, and Corrections to Misconceptions Related to Medical Cannabis' Active Pharmaceutical Ingredients' Physical Properties and Compositions. Cannabis and Cannabinoid Research. doi:10.1089/can.2021.0173 bron
  295. FAGG – Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (Belgie) (2015). Geneesmiddelen en andere producten op basis van cannabis of cannabidiol – FAQ. fagg-afmps.be. bron
  296. FAGG – Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (Belgie) (2015). Vragen over medicinale cannabis. fagg.be. bron
  297. FAGG – Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (Belgie) (2015). Informatie voor reizigers – verdovende middelen en psychotropen. fagg-afmps.be. bron
  298. Fairhurst C, Kumar R, Checketts D, Tayo B, Turner S (2020). Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Developmental Medicine & Child Neurology. doi:10.1111/dmcn.14548 bron
  299. Fallon MT, Albert Lux E, McQuade R, et al. (2017). Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain. doi:10.1177/2049463717710042 bron
  300. Farmacotherapeutisch Kompas (2024). Neuropathische pijn — indicatietekst. farmacotherapeutischkompas.nl. bron
  301. Farmacotherapeutisch Kompas (College ter Beoordeling van Geneesmiddelen) (2024). Clusterhoofdpijn — indicatietekst. Farmacotherapeutisch Kompas. bron
  302. Farmacotherapeutisch Kompas (Zorginstituut Nederland) (actueel). Cannabis (medicinaal) — preparaattekst. Farmacotherapeutisch Kompas. bron
  303. Farmatec (CIBG, ministerie van VWS) (2025). Opiumwet uitgebreid met lijst IA: NPS-wetswijziging per 1 juli 2025 van kracht. farmatec.nl. bron
  304. FBTO (2021). Vragen gezondheidsverklaring Overlijdensrisicoverzekering. fbto.nl. bron
  305. Federatie Medisch Specialisten / Richtlijnendatabase (2020). Medicinale cannabis bij de ziekte van Parkinson (Richtlijn Ziekte van Parkinson). Richtlijnendatabase.nl. bron
  306. Ferber SG, Namdar D, Hen-Shoval D, et al. (2020). The 'Entourage Effect': Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. Current Neuropharmacology. doi:10.2174/1570159X17666190903103923 bron
  307. Ferreira I, Lopes CM, Amaral MH (2024). Treatment Advances for Acne Vulgaris: The Scientific Role of Cannabinoids. Cosmetics 11(1):22. doi:10.3390/cosmetics11010022 bron
  308. Ferretti ML, et al. (2024). Examination of the effects of cannabidiol on menstrual-related symptoms. Experimental and Clinical Psychopharmacology 32(6):745-755. doi:10.1037/pha0000709 bron
  309. Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (2022). Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD013444.pub2 bron
  310. Finlay DB, Sircombe KJ, Nimick M, Jones C, Glass M (2020). Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors. Frontiers in Pharmacology 11:359. doi:10.3389/fphar.2020.00359 bron
  311. Fischedick JT, Hazekamp A, Erkelens T, Choi YH, Verpoorte R (2010). Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotypic and putative chemotaxonomic classification. Phytochemistry. doi:10.1016/j.phytochem.2010.08.002 bron
  312. Fitzcharles MA, Ste-Marie PA, Häuser W, et al. (2016). Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. Arthritis Care & Research (Hoboken). doi:10.1002/acr.22727 bron
  313. Foglia E, Schoeler T, Klamerus E, Morgan C, Bhattacharyya S (2017). Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychological Medicine. bron
  314. Food and Drug Administration, Thailand (2024). Guideline of Importation for Personal Use — Bringing of Health Products. Thai FDA (en.fda.moph.go.th). bron
  315. Foundation for Prader-Willi Research (2024). Cannabidivarin (CBDV) vs Placebo in Children with PWS. FPWR. bron
  316. Francisco AP, Lethbridge G, Patterson B, Bergmann CG, Van Ameringen M (2022). Cannabis use in Attention-Deficit/Hyperactivity Disorder (ADHD): A scoping review. Journal of Psychiatric Research. bron
  317. Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, Saunders R, Freeman TP (2019). How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neuroscience & Biobehavioral Reviews, 107:696-712. doi:10.1016/j.neubiorev.2019.09.036 bron
  318. Freitas MET, Fox SH (2024). Advice to People with Parkinson's in My Clinic: Cannabis. Journal of Parkinson's Disease. doi:10.3233/JPD-230358 bron
  319. Fuhr LM, Marok FZ, Hanke N, Selzer D, Lehr T (2023). Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7-Dihydroxybergamottin to Describe CYP3A4-Mediated Grapefruit-Drug Interactions. Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.2968 bron
  320. Fuss J, Steinle J, Bindila L, Auer MK, Kirchherr H, Lutz B, Gass P (2015). A runner's high depends on cannabinoid receptors in mice. Proceedings of the National Academy of Sciences (PNAS). doi:10.1073/pnas.1514996112 bron
  321. Gamble LJ, Boesch JM, Frye CW, et al. (2018). Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science. doi:10.3389/fvets.2018.00165 bron
  322. Gedin F, Blomé S, Pontén M, et al. (2022). Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis. JAMA Network Open. doi:10.1001/jamanetworkopen.2022.43848 bron
  323. GEINO-1601 investigators (2024). 454P Tetrahydrocannabinol (THC)/cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial. Annals of Oncology. doi:10.1016/j.annonc.2024.08.524 bron
  324. Geneesmiddelenbulletin (Ge-Bu) (2019). Medicinale cannabis en cannabinoïden. Geneesmiddelenbulletin. bron
  325. Geneesmiddelenbulletin (Ge-Bu) (2019). Medicinale cannabis. ge-bu.nl. bron
  326. Gertsch J, Leonti M, Raduner S, et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences (PNAS) 105(26):9099-9104. doi:10.1073/pnas.0803601105 bron
  327. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D (2019). Association Between Marijuana Use and Risk of Cancer: A Systematic Review and Meta-analysis. JAMA Network Open. doi:10.1001/jamanetworkopen.2019.16318 bron
  328. Ghorayeb I (2020). More evidence of cannabis efficacy in restless legs syndrome. Sleep and Breathing. doi:10.1007/s11325-019-01978-1 bron
  329. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP (2015). Cannabis use and mania symptoms: a systematic review and meta-analysis. Journal of Affective Disorders. doi:10.1016/j.jad.2014.09.016 bron
  330. Gidal BE, Vandrey R, Wallin C, e.a. (2024). Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. Frontiers in Pharmacology. doi:10.3389/fphar.2024.1335441 bron
  331. Gieringer D, St. Laurent J, Goodrich S (2004). Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds. Journal of Cannabis Therapeutics. doi:10.1300/J175v04n01_02 bron
  332. Giorgi V, Marotto D, Batticciotto A, Atzeni F, Bongiovanni S, Sarzi-Puttini P (2021). Cannabis and Autoimmunity: Possible Mechanisms of Action. ImmunoTargets and Therapy. doi:10.2147/ITT.S267905 bron
  333. Gloss D, Vickrey B. (2014). Cannabinoids for epilepsy. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD009270.pub3 bron
  334. Gobierno de España (Ministerio de Sanidad) (2025). Real Decreto 903/2025, de 7 de octubre, por el que se regula el uso medicinal del cannabis. Boletín Oficial del Estado (BOE). bron
  335. Gorbenko AA, et al. (2024). Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Delta-9-Tetrahydrocannabinol Without Improving Its Analgesic Properties. Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.3381 bron
  336. Gorelick DA, Levin KH, Copersino ML, et al. (zie ook Livne O et al. 2019) (2019). DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2018.09.005 bron
  337. GOV.UK (2024). Take medicine in or out of the UK. GOV.UK. bron
  338. Government of Canada (2018). Cannabis Act (SC 2018, c. 16). laws-lois.justice.gc.ca. bron
  339. Government of Canada (2024). Drugs, alcohol and travel. travel.gc.ca. bron
  340. Goyal H, Awad HH, Ghali JK (2017). Role of cannabis in cardiovascular disorders. Journal of Thoracic Disease. doi:10.21037/jtd.2017.06.104 bron
  341. Grayson L, Vines B, Nichol K, Szaflarski JP (2017). An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports. doi:10.1016/j.ebcr.2017.10.001 bron
  342. Grimison P, Mersiades A, Kirby A, et al. (2020). Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Annals of Oncology, 31(11):1553-1560. doi:10.1016/j.annonc.2020.07.020 bron
  343. Grimison P, Mersiades A, Kirby A, et al. (2024). Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. Journal of Clinical Oncology. doi:10.1200/JCO.23.01836 bron
  344. Groenten & Fruit Actueel (2024). Telers kunnen in 2027 ook apothekers met cannabis beleveren. gfactueel.nl. bron
  345. Grotenhermen F (2003). Clinical Pharmacokinetics of Cannabinoids. Clinical Pharmacokinetics. bron
  346. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics. doi:10.2165/00003088-200342040-00003 bron
  347. Guggisberg J, Schumacher M, Gilmore G, Zylla DM (2022). Cannabis as an Anticancer Agent: A Review of Clinical Data and Assessment of Case Reports. Cannabis and Cannabinoid Research. doi:10.1089/can.2021.0045 bron
  348. Guimarães-Lopes VP, Gomes MS, Lopes NP, Taniwaki NN, da Silva Filho AA, Ambrosio SR, Veneziani RCS, Cascón V (2017). Metabolic Products of Linalool and Modulation of GABAA Receptors. Frontiers in Chemistry 5:46. doi:10.3389/fchem.2017.00046 bron
  349. Gunasekaran N, Long LE, Dawson BL, et al. (2009). Reintoxication: the release of fat-stored Δ9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2009.00276.x bron
  350. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L (2006). A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer. doi:10.1038/sj.bjc.6603236 bron
  351. GW Pharmaceuticals (persbericht via CURE Epilepsy) (2018). GW Pharmaceuticals Announces That Pipeline Compound GWP42006 (cannabidivarin) Did Not Meet Primary Endpoint in Phase 2a Study. CURE Epilepsy. bron
  352. GW Pharmaceuticals plc (2018). FDA Approval of EPIDIOLEX (cannabidiol) oral solution - the First Plant-derived Cannabinoid Prescription Medicine. GW Pharmaceuticals Investor Relations. bron
  353. Gwinn KD, Leung M, Stephens A, Punja ZK (2023). Fungal and mycotoxin contaminants in cannabis and hemp flowers: implications for consumer health and directions for further research. Frontiers in Microbiology. doi:10.3389/fmicb.2023.1278189 bron
  354. Habib AM, Okorokov AL, Hill MN, et al. (2019). Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. British Journal of Anaesthesia 123(2):e249-e253. doi:10.1016/j.bja.2019.02.019 bron
  355. Hancox RJ, Shin HH, Gray AR, Poulton R, Sears MR (2015). Effects of quitting cannabis on respiratory symptoms. European Respiratory Journal. doi:10.1183/09031936.00228914 bron
  356. Hansen JS, Hansen RM, Petersen T, et al. (2023). Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. Pharmaceuticals (Basel). doi:10.3390/ph16081079 bron
  357. Harada H, Kashiwadani H, Kanmura Y, Kuwaki T (2018). Linalool Odor-Induced Anxiolytic Effects in Mice. Frontiers in Behavioral Neuroscience 12:241. doi:10.3389/fnbeh.2018.00241 bron
  358. Hartman RL, Brown TL, Milavetz G, et al. (2016). Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug Testing and Analysis. doi:10.1002/dta.1839 bron
  359. Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA (2015). Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. Clinical Chemistry. doi:10.1373/clinchem.2015.238287 bron
  360. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Kaabi JA, Ojha S (2021). A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomedicine & Pharmacotherapy 140:111639. doi:10.1016/j.biopha.2021.111639 bron
  361. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. European Journal of Clinical Pharmacology. bron
  362. Häuser W, Welsch P, Klose P, Radbruch L, Fitzcharles MA (2019). Efficacy, tolerability and safety of cannabis-based medicines for cancer pain: a systematic review with meta-analysis of randomised controlled trials. Schmerz 33(5):424-436. doi:10.1007/s00482-019-0373-3 bron
  363. Hauser W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA (2023). Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD014915.pub2 bron
  364. Hazekamp A (2016). Evaluating the Effects of Gamma-Irradiation for Decontamination of Medicinal Cannabis. Frontiers in Pharmacology. doi:10.3389/fphar.2016.00108 bron
  365. Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R (2007). Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. Journal of Ethnopharmacology 113(1):85-90. doi:10.1016/j.jep.2007.05.019 bron
  366. Hazekamp A, Epifanova S (2017). Grote variatie in samenstelling cannabisolie noopt tot regels. Pharmaceutisch Weekblad (2017;152:44). bron
  367. Hazekamp A, Heerdink ER, et al. (2018). Medicinal Cannabis on Prescription in The Netherlands: Statistics for 2003-2016. Cannabis and Cannabinoid Research / NCBI PMC. bron
  368. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R (2006). Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. Journal of Pharmaceutical Sciences. doi:10.1002/jps.20574 bron
  369. Health Canada (2024). Section 56 Class Exemption For Travellers Who Are Importing or Exporting Prescription Drug Products Containing a Narcotic or a Controlled Drug. canada.ca. bron
  370. Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR Jr (2022). A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis. Journal of Hand Surgery (American Volume). doi:10.1016/j.jhsa.2022.03.002 bron
  371. Hepler RS, Frank IR (1971). Marihuana smoking and intraocular pressure. JAMA 217(10):1392. bron
  372. Herdegen T, Cascorbi I (2023). Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs: Recommendations for Clinical Practice. Deutsches Arzteblatt International. doi:10.3238/arztebl.m2023.0223 bron
  373. Herkenham M, Lynn AB, Little MD, et al. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences (PNAS). doi:10.1073/pnas.87.5.1932 bron
  374. Hermush et al. (2025). Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation. Journal of Cannabis Research. doi:10.1186/s42238-025-00294-8 bron
  375. Hermush V, Ore L, Stern N, et al. (2022). Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Frontiers in Medicine. doi:10.3389/fmed.2022.951889 bron
  376. Herrmann ES, Cone EJ, Mitchell JM, et al. (2015). Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2015.04.020 bron
  377. Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanctôt KL (2019). Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. The American Journal of Geriatric Psychiatry. doi:10.1016/j.jagp.2019.05.002 bron
  378. Herrstedt J, et al. (MASCC/ESMO consensus) (2023). 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. Supportive Care in Cancer / ESMO Open. bron
  379. Hersentumorcentrum Nederland (2024). Cannabis onderzoek bij hersentumoren. hersentumorcentrum.nl. bron
  380. Hesketh PJ, Kris MG, Basch E, et al. (2020). Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology. doi:10.1200/JCO.20.01296 bron
  381. Hill MN et al. (2015). Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology. doi:10.1038/npp.2015.166 bron
  382. Hillard CJ (2015). The Endocannabinoid Signaling System in the CNS: A Primer. International Review of Neurobiology. doi:10.1016/bs.irn.2015.10.001 bron
  383. Hillard CJ (2017). Endocannabinoid Signaling and the Hypothalamic-Pituitary-Adrenal Axis. Comprehensive Physiology. bron
  384. Hindocha C, McClure B (2021). Unknown population-level harms of cannabis and tobacco co-use: if you don't measure it, you can't manage it. Addiction. doi:10.1111/add.15290 bron
  385. Hirsch H (Harvard Health Publishing) (2022). Are women turning to cannabis for menopause symptom relief?. Harvard Health Blog. bron
  386. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry. doi:10.1038/mp.2011.82 bron
  387. Ho C, et al. (2024). Evaluation of potential drug–drug interactions with medical cannabis. Clinical and Translational Science. doi:10.1111/cts.13812 bron
  388. Ho JH, Bhatt DL, Sasson I, et al. (2024). Evaluation of potential drug-drug interactions with medical cannabis. Clinical and Translational Science. doi:10.1111/cts.13812 bron
  389. Hof Leeuwarden (2011). Verzwijging drugsverleden bij aangaan verzekering; buitengerechtelijke kosten ass afgewezen. Arbeidsongeschiktheidsmagazine.nl / rechtspraak.nl. bron
  390. Home Office (2024). Travelling with medicine containing controlled drugs. GOV.UK. bron
  391. Hoogendoorn K (WRR) (2026). 150 jaar Nederlands drugsbeleid: Een tegenstrijdig evenwicht. Wetenschappelijke Raad voor het Regeringsbeleid (wrr.nl). bron
  392. Hsu A, Painter NA (2020). Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis. Journal of Pharmacy Practice 33(6):915-918. doi:10.1177/0897190019854958 bron
  393. Huestis MA (2007). Human Cannabinoid Pharmacokinetics. Chemistry & Biodiversity. doi:10.1002/cbdv.200790152 bron
  394. Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012). An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. British Journal of Anaesthesia 109(5):721-728. doi:10.1093/bja/aer464 bron
  395. Huis Advocaten (2021). Bijzondere bijstand voor medicinale cannabis. huisadvocaten.nl. bron
  396. Huisartsgeneeskunde / Bohn Stafleu van Loghum (2023). Medicinale cannabis voorschrijven. huisarts.bsl.nl. bron
  397. Huisartsgeneeskunde / NHG (2023). Procedure voor voorschrijven van medicinale cannabis. huisarts.bsl.nl. bron
  398. Hukkanen J, Jacob P, Benowitz NL (2011). Effect of nicotine on cytochrome P450 1A2 activity. British Journal of Clinical Pharmacology. doi:10.1111/j.1365-2125.2011.04023.x bron
  399. Hulaihel A, Gliksberg O, Feingold D, Brill S, Amit BH, Lev-Ran S, Sznitman SR (2023). Medical cannabis and stigma: A qualitative study with patients living with chronic pain. Journal of Clinical Nursing. doi:10.1111/jocn.16340 bron
  400. Hunziker S, Morosoli F, Zuercher K, Tscherter A, Grunt S (2023). Prescription Practices of Cannabinoids in Children with Cerebral Palsy Worldwide—A Survey of the Swiss Cerebral Palsy Registry. Children. doi:10.3390/children10121838 bron
  401. Hurd YL, Spriggs S, Alishayev J, et al. (2019). Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. American Journal of Psychiatry. doi:10.1176/appi.ajp.2019.18101191 bron
  402. Hurley EN, Ellaway CJ, Johnson AM, et al. (2022). Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia. doi:10.1111/epi.17247 bron
  403. Ibrahim BM, Abdel-Rahman AA (2014). Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A review. Journal of Advanced Research. bron
  404. ICS 2020 (abstract #45) (2020). Patient perspectives on cannabinoids for interstitial cystitis/bladder pain syndrome. International Continence Society Annual Meeting Abstracts. bron
  405. IKNL / kanker.nl (2025). Hoe gebruik je cannabis bij kanker?. kanker.nl. bron
  406. Inchingolo F, et al. (2021). Cannabinoids Drugs and Oral Health—From Recreational Side-Effects to Medicinal Purposes: A Systematic Review. International Journal of Molecular Sciences. doi:10.3390/ijms22158329 bron
  407. Informatiecentrum Cannabis (2025). Opiumwet: lijst I en lijst II. informatiecentrumcannabis.nl. bron
  408. Inspectie Justitie en Veiligheid (2025). Fasering wietexperiment. inspectie-jenv.nl. bron
  409. Instituut Medicinale Cannabis (2021). Ministerie verlaagt apotheekprijs medicinale cannabis. imc-nederland.nl. bron
  410. Instituut Medicinale Cannabis (IMC Nederland) (2024). Gebruik van medicinale cannabis. imc-nederland.nl. bron
  411. Instituut Medicinale Cannabis (IMC) (2024). Bijwerkingen & risico's van medicinale cannabis. imc-nederland.nl. bron
  412. Internationaal Journal of Legal Medicine (systematische review) (2026). Impact of CBD and hemp oil use on drug test results: a systematic review. International Journal of Legal Medicine. doi:10.1007/s00414-026-03790-5 bron
  413. International Association for the Study of Pain (IASP) Presidential Task Force on Cannabis and Cannabinoid Analgesia (2021). IASP Position Statement on the Use of Cannabinoids to Treat Pain. International Association for the Study of Pain (IASP). bron
  414. IPWatchdog (2020). Patenting Cannabis: Possibilities and Pitfalls. IPWatchdog.com. bron
  415. Irvine D, et al. (2026). Cannabis and Anesthesia: A 2025 Update on Perioperative Considerations. APSF Newsletter 41(1). bron
  416. Ito K, Ito M (2013). The sedative effect of inhaled terpinolene in mice and its structure–activity relationships. Journal of Natural Medicines. doi:10.1007/s11418-012-0732-1 bron
  417. Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Lembo F, Capasso F, Orlando P, Di Marzo V (2012). Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2012.01879.x bron
  418. Jackson NJ, Isen JD, Khoddam R, et al. (2016). Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proceedings of the National Academy of Sciences (PNAS). doi:10.1073/pnas.1516648113 bron
  419. Jadoon KA, Ratcliffe SH, Barrett DA, et al. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. doi:10.2337/dc16-0650 bron
  420. Jaidee W, Siridechakorn I, Nessopa S, et al. (2022). Kinetics of CBD, Delta9-THC Degradation and Cannabinol Formation in Cannabis Resin at Various Temperature and pH Conditions. Cannabis and Cannabinoid Research 7(4):537-547. doi:10.1089/can.2021.0004 bron
  421. Jakubovski E, Pisarenko A, Fremer C, et al. (2022). Implications for blinding in clinical trials with THC-containing cannabinoids based on the CANNA-TICS trial. Frontiers in Neuroscience. doi:10.3389/fnins.2022.793703 bron
  422. Jatoi A, Windschitl HE, Loprinzi CL, et al. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. Journal of Clinical Oncology 20(2):567-573. doi:10.1200/JCO.2002.20.2.567 bron
  423. Javid F, et al. (2025). Recent Advances in the Therapeutic Potential of Cannabinoids Against Gliomas: A Systematic Review (2022–2025). Pharmacology Research & Perspectives. doi:10.1002/prp2.70160 bron
  424. Jazz Pharmaceuticals / EMA (2024). Epidyolex 100 mg/ml oral solution - Summary of Product Characteristics. electronic medicines compendium (emc). bron
  425. Jeffers AM, Glantz S, Byers AL, Keyhani S (2024). Association of Cannabis Use With Cardiovascular Outcomes Among US Adults. Journal of the American Heart Association. doi:10.1161/JAHA.123.030178 bron
  426. Jellinek (2024). Leiden hasj en wiet tot blijvende hersenschade?. Jellinek.nl (vraag & antwoord). bron
  427. Jellinek (2024). Welke invloed heeft cannabis op het verkeer?. jellinek.nl. bron
  428. Jellinek (2024). Wat gebeurt er bij de combinatie alcohol en cannabis?. Jellinek.nl. bron
  429. Jellinek (2024). Cannabis - ADHD medicatie. Jellinek (verslavingszorg). bron
  430. Jellinek (z.j.). Cannabis en borstvoeding. Jellinek.nl. bron
  431. Jellinek (2024). Mag je als minderjarige op straat blowen?. Jellinek.nl. bron
  432. Jellinek (2024). Welke regels gelden er voor de coffeeshops?. Jellinek.nl. bron
  433. Jellinek (Arkin) (2024). Wat zijn de risico's van wiet?. Jellinek.nl. bron
  434. Jellinek (Arkin) (actueel). Is cannabis meer of minder schadelijk voor de longen dan tabak?. Jellinek (jellinek.nl). bron
  435. Jellinek (Arkin) (2024). Kun je verslaafd raken aan cannabis?. jellinek.nl - vraag & antwoord. bron
  436. Jellinek (Arkin) (2024). Cannabis - Diabetes. Jellinek.nl (drugs en medicijnen combinaties). bron
  437. Jellinek (kennis- en behandelinstelling verslavingszorg) (z.j.). Hoe werkt de opname, het effect en de afbraak van cannabis?. Jellinek (Vraag en antwoord). bron
  438. Jellinek (Stichting Arkin) (2024). Wat is CBD (Cannabidiol)?. Jellinek.nl. bron
  439. Jellinek (verslavingszorg) (2026). Wat zijn de risico's van CBD-olie of cannabisolie?. jellinek.nl. bron
  440. Jellinek (verslavingszorg) (2020). Wat is het cannabinoïd-hyperemesis-syndroom?. Jellinek.nl. bron
  441. Jellinek (verslavingszorg) (2024). Wat zijn de risico's van spacecake?. jellinek.nl. bron
  442. Jellinek (verslavingszorg) (2024). Cannabis en pijnmedicatie — drugs en medicijnen combineren. Jellinek.nl. bron
  443. Jellinek (verslavingszorg) (2023). Hoeveel mensen zijn verslaafd aan cannabis en hoeveel komen in behandeling?. Jellinek.nl. bron
  444. Jellinek (verslavingszorg) (actueel). Waarom is gebruik van drugs op jonge leeftijd extra slecht?. Jellinek. bron
  445. Jellinek (verslavingszorg) (2024). Hoe ontstaan ontwenningsverschijnselen bij cannabis?. Jellinek.nl. bron
  446. Jellinek (verslavingszorg) (2024). Kan cannabis schizofrenie of een psychose veroorzaken?. Jellinek.nl. bron
  447. Jellinek (verslavingszorg) (2024). Wat is de geschiedenis van cannabis?. Jellinek.nl. bron
  448. Jergova S, et al. (2022). Evaluation of cannabis constituents in preventing or reversing phantom limb pain in rats (CCORC 2022 abstract). Medical Cannabis and Cannabinoids (CCORC Proceedings). doi:10.1159/000551763 bron
  449. Jetly R, Heber A, Fraser G, Boisvert D (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. doi:10.1016/j.psyneuen.2014.11.002 bron
  450. Johns Hopkins Medicine (2024). Clinical Trial Shows Synthetic Cannabis Reduces Agitation in Alzheimer's Disease. Johns Hopkins Medicine Newsroom. bron
  451. Johns Hopkins University (2020). Behavioral Pharmacology of THC and Alpha-pinene. ClinicalTrials.gov. bron
  452. Johnson DA, Funnell MP, Heaney LM, et al. (2024). Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males. Cannabis and Cannabinoid Research. doi:10.1089/can.2023.0117 bron
  453. Jordan-Ríos A, et al. (StatPearls) (2023). Cannabis Use for Glaucoma and Associated Pain. StatPearls, NCBI Bookshelf (NBK572112). bron
  454. Joyce KM, Thompson K, Good KP, Tibbo PG, O'Leary ME, Perrot TS, Hudson A, Stewart SH (2021). The impact of depressed mood and coping motives on cannabis use quantity across the menstrual cycle in those with and without pre-menstrual dysphoric disorder. Addiction 116(10):2746-2758. doi:10.1111/add.15465 bron
  455. Justitiële Informatiedienst (2024). Strafblad en minderjarigen. JustID.nl. bron
  456. Kafil TS, Nguyen TM, MacDonald JK, Chande N (2020). Cannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews. Inflammatory Bowel Diseases. doi:10.1093/ibd/izz233 bron
  457. Kafil TS, Nguyen TM, MacDonald JK, Chande N (2018). Cannabis for the treatment of ulcerative colitis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD012954.pub2 bron
  458. Kanker.nl (IKNL / KWF / NFK) (2024). Cannabis, CBD en THC bij kanker. kanker.nl. bron
  459. Kanker.nl (IKNL / KWF / NFK) (2026). Cannabis, CBD en THC bij kanker. kanker.nl. bron
  460. Kanker.nl (IKNL en patiëntenorganisaties) (2026). Cannabis, CBD en THC bij kanker. kanker.nl. bron
  461. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009). Endocannabinoid-mediated control of synaptic transmission. Physiological Reviews. doi:10.1152/physrev.00019.2008 bron
  462. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011). Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-THC and Oromucosal Cannabis Extract Administration. Clinical Chemistry (PMC3717338). doi:10.1373/clinchem.2010.157719 bron
  463. Karst M, Meissner W, Sator S, et al. (2025). Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nature Medicine. doi:10.1038/s41591-025-03977-0 bron
  464. Kasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A (2014). Silexan in generalized anxiety disorder — a randomized, double-blind comparison to placebo and paroxetine. International Journal of Neuropsychopharmacology 17(6):859-869. doi:10.1093/ijnp/pyu063 bron
  465. Kayser RR, et al. (2020). Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder. Depression and Anxiety / J Clin Psychopharmacol. bron
  466. Kayser RR, et al. (2025). New treatments for OCD? Evidence for cannabinoids and psychedelics. Journal of Psychiatric Research. bron
  467. Kearsey LJ, et al. (2023). Biosynthesis of cannabigerol and cannabigerolic acid: the gateways to further cannabinoid production. Synthetic Biology (Oxford). doi:10.1093/synbio/ysac025 bron
  468. Kebede V, Arnold JC, et al. (2025). A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats. Neuropsychopharmacology. doi:10.1038/s41386-024-02018-7 bron
  469. Kerbrat A, Ferre JC, Fillatre P, et al. (2016). Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase. New England Journal of Medicine 375(18):1717-1725. doi:10.1056/NEJMoa1604221 bron
  470. Khan SS, Secades-Villa R, Okuda M, et al. (2013). Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2012.10.015 bron
  471. Kimless D, Caloura MK, Goldner S (2021). Cannabidiol (CBD) For the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet: A Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Diabetes & Metabolism. bron
  472. King DD, Gill CJ, Cadieux CS, Singh N (2024). The role of stigma in cannabis use disclosure: an exploratory study. Harm Reduction Journal. doi:10.1186/s12954-024-00929-8 bron
  473. Kinsey SG, Llorente-Berzal A (2026). FAAH and MAGL inhibition: Evolving approaches to treating substance use disorders. Pharmacology Biochemistry and Behavior. doi:10.1016/j.pbb.2025.173966 bron
  474. Kitdumrongthum S, Trachootham D (2023). An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products. Molecules. doi:10.3390/molecules28062791 bron
  475. Klachtenportaal Zorg (2024). Klachtenportaal Zorg. klachtenportaalzorg.nl. bron
  476. Klauke AL, Racz I, Pradier B, Markert A, Zimmer AM, Gertsch J, Zimmer A (2014). The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. European Neuropsychopharmacology. bron
  477. Klein P, Tolbert D, Gidal BE (2019). Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy & Behavior. doi:10.1016/j.yebeh.2019.106459 bron
  478. Kleiner D, et al. (2023). Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. Current Neuropharmacology 21(12):2505-2515. doi:10.2174/1570159X21666230727094431 bron
  479. Klumpers LE, Beumer TL, van Hasselt JGC, et al. (2012). Novel Delta-9-tetrahydrocannabinol formulation Namisol has beneficial pharmacokinetics and promising pharmacodynamic effects. British Journal of Clinical Pharmacology. doi:10.1111/j.1365-2125.2012.04164.x bron
  480. KNMG (2024). Behandelingsovereenkomst (WGBO). knmg.nl — Dossier Patiëntenrechten. bron
  481. KNMG (2024). Informed consent. knmg.nl — Dossier Patiëntenrechten. bron
  482. KNMG (2024). Rechten van de patiënt. knmg.nl — Dossier Patiëntenrechten. bron
  483. KNMG (Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst) (2022). Heeft mijn patiënt recht op een verwijzing voor een second opinion?. knmg.nl. bron
  484. KNMP (2022). Nieuwe bijlage 2-voorwaarden voor geneesmiddelen: onder meer voor cannabidiol. knmp.nl. bron
  485. KNMP (Apotheek.nl) (z.j.). Cannabis: bijwerkingen, autorijden en gebruik. apotheek.nl. bron
  486. KNMP (Apotheek.nl) (2026). Dronabinol (Marinol): waarvoor, gebruik en beschikbaarheid. Apotheek.nl (KNMP). bron
  487. KNMP (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie) (2026). Cannabis (marihuana, medicinaal): contra-indicaties, waarschuwingen en autorijden. Apotheek.nl. bron
  488. KNMP Geneesmiddel Informatie Centrum en Nederlands Huisartsen Genootschap (NHG) (2025). Vergiftiging. Apotheek.nl. bron
  489. Kocis PT, Vrana KE; Antoniou T, et al. (2022). Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. Drug Safety / PMC. bron
  490. Kollins SH, Schoenfelder EN, English JS, Holdaway A, Van Voorhees E, Turic K, Dorval M (2015). An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. Journal of Substance Abuse Treatment. bron
  491. Kolobaric A, et al. (2024). A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of CBN for Improving Sleep. Pharmaceuticals (Basel). doi:10.3390/ph17080977 bron
  492. Koninklijke Nederlandse Maatschappij voor Diergeneeskunde (KNMvD) (2022). De nieuwe cascaderegeling onder Verordening (EU) 2019/6. KNMvD.nl. bron
  493. Koppel BS, Brust JCM, Fife T, et al. (2014). Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders (American Academy of Neurology). Neurology 82(17):1556-1563. doi:10.1212/WNL.0000000000000363 bron
  494. Kopruszinski CM, Navratilova E, Vagnerova B, Swiokla J, Patwardhan A, Dodick D, Porreca F (2020). Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. doi:10.1177/0333102419865252 bron
  495. Kosovic E, Sykora D, Kuchar M (2021). Stability Study of Cannabidiol in the Form of Solid Powder and Sunflower Oil Solution. Pharmaceutics 13(3):412. doi:10.3390/pharmaceutics13030412 bron
  496. Krishnasamy VP, Hallowell BD, Ko JY, et al. (2020). Update: Characteristics of a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury - United States, August 2019-January 2020. MMWR Morbidity and Mortality Weekly Report 2020;69:90-94. doi:10.15585/mmwr.mm6903e2 bron
  497. Kuhathasan N, et al. (2022). Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far. Nature and Science of Sleep. doi:10.2147/NSS.S340949 bron
  498. KWF Kankerbestrijding (2024). Standpunt cannabis en wietolie. kwf.nl. bron
  499. Lachenmeier DW, Habel S, Fischer B, et al. (2024). Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?. F1000Research 8:1394 (versie 7). doi:10.12688/f1000research.19931.7 bron
  500. Lanz C, Mattsson J, Soydaner U, Brenneisen R (2016). Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PLoS ONE. doi:10.1371/journal.pone.0147286 bron
  501. Lapoint J, Meyer S, Yu CK, et al. (2017). Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline. Western Journal of Emergency Medicine. bron
  502. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology. doi:10.1111/bph.13250 bron
  503. Laux-Biehlmann A et al. (2024). Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Frontiers in Pharmacology. bron
  504. Lavender I, Garden G, Grunstein RR, et al. (2023). Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. BMJ Open. doi:10.1136/bmjopen-2022-071148 bron
  505. Lavender IG, Hoyos CM, Suraev A, et al. (2026). Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. Journal of Sleep Research. doi:10.1111/jsr.70284 bron
  506. LaVigne JE, Hecksel R, Keresztes A, Streicher JM (2021). Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Scientific Reports 11:8232. doi:10.1038/s41598-021-87740-8 bron
  507. Lee C, Danielson EC, Beestrum M, et al. (2023). Medical Cannabis and Its Efficacy/Effectiveness for the Treatment of Low-Back Pain: a Systematic Review. Current Pain and Headache Reports. doi:10.1007/s11916-023-01189-0 bron
  508. Lee JH, Yoon JY, Kim DH, Kwon YG, Kim GH, Park BJ, Suh DH (2024). Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. Archives of Dermatological Research 316:428. doi:10.1007/s00403-024-03131-9 bron
  509. Leino AD, et al. (2022). Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation. bron
  510. Leite GO, Barbosa LM, Figueiredo IS, et al. (2021). Pharmacological and toxicological activities of α-humulene and its isomers: A systematic review. Trends in Food Science and Technology. doi:10.1016/j.tifs.2021.06.049 bron
  511. Lemberger L, Crabtree RE, Rowe HM (1972). 11-Hydroxy-delta9-tetrahydrocannabinol: Pharmacology, Disposition, and Metabolism of a Major Metabolite of Marihuana in Man. Science. doi:10.1126/science.177.4043.62 bron
  512. Leroux E, Taifas I, Valade D, Donnet A, Chagnon M, Ducros A (2013). Use of cannabis among 139 cluster headache sufferers. Cephalalgia. doi:10.1177/0333102412468669 bron
  513. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry. doi:10.1038/tp.2012.15 bron
  514. Li H, et al. (2024). Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. Molecules. doi:10.3390/molecules29225471 bron
  515. Linares IMP, Guimarães FS, Eckeli A, et al. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry. doi:10.1590/1516-4446-2017-0015 bron
  516. Liu Y, Bainbridge J, Sillau S, et al. (2024). Short-term cannabidiol with delta-9-tetrahydrocannabinol in Parkinson disease: a randomized trial. Movement Disorders. doi:10.1002/mds.29768 bron
  517. Lo JO, Ayers CK, Yeddala S, et al. (2025). Prenatal Cannabis Use and Neonatal Outcomes: A Systematic Review and Meta-Analysis. JAMA Pediatrics. doi:10.1001/jamapediatrics.2025.0689 bron
  518. Lo JO, Shaw B, Robalino S, et al. (2024). Cannabis Use in Pregnancy and Neonatal Outcomes: A Systematic Review and Meta-Analysis. Cannabis and Cannabinoid Research. doi:10.1089/can.2022.0262 bron
  519. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA (2023). Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. Journal of Internal Medicine. doi:10.1111/joim.13627 bron
  520. Lopera V, Rodríguez A, Amariles P (2022). Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. Journal of Clinical Medicine 11(5):1154. doi:10.3390/jcm11051154 bron
  521. Lopera V, Rodríguez A, Amariles P (2022). Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. Journal of Clinical Medicine. doi:10.3390/jcm11051154 bron
  522. Lopes D et al. (2025). Cannabis extract in treatment of narcolepsy: A case report. Sleep Medicine. bron
  523. López-Olmos, C.; García-Valverde, M.T.; Hidalgo, J.; Ferreiro-Vera, C.; Sánchez de Medina, V. (2022). Comprehensive comparison of industrial cannabinoid extraction techniques: Evaluation of the most relevant patents and studies at pilot scale. Frontiers in Natural Products. doi:10.3389/fntpr.2022.1043147 bron
  524. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C (2011). Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2010.11.004 bron
  525. Loprinzi CL, et al. (ASCO) (2020). Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology. doi:10.1200/JCO.20.01399 bron
  526. Lu HC, Mackie K (2021). Review of the Endocannabinoid System. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. doi:10.1016/j.bpsc.2020.07.016 bron
  527. Lucas CJ, Galettis P, Schneider J (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology. doi:10.1111/bcp.13710 bron
  528. Lucas CJ, Galettis P, Schneider J (en latere overzichten) (2018). The pharmacokinetics and pharmacodynamics of cannabinoids. British Journal of Clinical Pharmacology / pharmacokinetische overzichtsliteratuur. bron
  529. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017). Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.MR000033.pub3 bron
  530. Lupus Foundation of America (2024). Cannabis (Marijuana) and Lupus. lupus.org. bron
  531. Lynch ME, Cesar-Rittenberg P, Hohmann AG (2014). A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management. doi:10.1016/j.jpainsymman.2013.02.018 bron
  532. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PAF, Nelson EC, Statham DJ, Martin NG (2003). Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 289(4):427-433. doi:10.1001/jama.289.4.427 bron
  533. MacCallum CA, et al. (2024). Evaluation of potential drug-drug interactions with medical cannabis. Clinical Pharmacology (PMC). bron
  534. Macfarlane GJ, Kronisch C, Dean LE, et al. (2017). EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2016-209724 bron
  535. Mack J, et al. (2024). A survey-based, quasi-experimental study assessing a high-cannabidiol suppository for menstrual-related pain and discomfort. npj Women's Health. doi:10.1038/s44294-024-00032-0 bron
  536. Maddison KJ, Kosky C, Walsh JH (2022). Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far. Nature and Science of Sleep. doi:10.2147/NSS.S340949 bron
  537. Maghfour J, Rietcheck HR, Rundle CW, et al. (2020). An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin. Journal of Drugs in Dermatology. doi:10.36849/JDD.2020.5464 bron
  538. Magno LAV, Tameirão DR, Alves LF, Guimarães NS (2024). Effect of recreational cannabis use on bone mineral density: a systematic review. Osteoporosis International 35(3):391-399. doi:10.1007/s00198-023-06992-4 bron
  539. Mahmoudinoodezh H, Telukutla SR, Bhangu SK, et al. (2022). The Transdermal Delivery of Therapeutic Cannabinoids. Pharmaceutics. doi:10.3390/pharmaceutics14020438 bron
  540. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V (2011). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2010.01063.x bron
  541. Malta G, Albano GD, Lavanco G, Brancato A, Cannizzaro C (2025). Acute cannabis intoxication among the paediatric population. Frontiers in Toxicology 2025;7:1558721. doi:10.3389/ftox.2025.1558721 bron
  542. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016). Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia Bulletin. doi:10.1093/schbul/sbw003 bron
  543. Marijuana Moment (2024). UN Body Reaffirms That Marijuana Legalization Violates International Treaties, While Addressing Germany Cannabis Reform. Marijuana Moment. bron
  544. Masataka N (2019). Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders. Frontiers in Psychology. doi:10.3389/fpsyg.2019.02466 bron
  545. Mavedatnia D, Levin M, Lee JW, Hamour AF, Dizon K, Le T (2023). Cannabis use amongst tinnitus patients: consumption patterns and attitudes. Journal of Otolaryngology - Head & Neck Surgery. doi:10.1186/s40463-022-00603-8 bron
  546. McDonagh MS, Morasco BJ, Wagner J, et al. (2025). Cannabis-Based Products for Chronic Pain: An Updated Systematic Review. Annals of Internal Medicine. doi:10.7326/ANNALS-25-03152 bron
  547. McDougall JJ, McKenna MK (2022). Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis. International Journal of Molecular Sciences 23(14):7891. doi:10.3390/ijms23147891 bron
  548. McGilveray IJ (2005). Pharmacokinetics of cannabinoids. Pain Research & Management. doi:10.1155/2005/242516 bron
  549. McGuire P, Robson P, Cubala WJ, et al. (2018). Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry. doi:10.1176/appi.ajp.2017.17030325 bron
  550. McLaren K, Erridge S, Sodergren MH (2025). A Scoping Systematic Review of Cannabis Use in Endometriosis. Australian and New Zealand Journal of Obstetrics and Gynaecology. doi:10.1111/ajo.70081 bron
  551. Meah F, Lundholm M, Emanuele N, et al. (2022). The effects of cannabis and cannabinoids on the endocrine system. Reviews in Endocrine and Metabolic Disorders. doi:10.1007/s11154-021-09682-w bron
  552. Medical Cannabis Clinicians Society (MCCS) (2024). Good Practice Guide May 2024: The Medical Cannabis Clinicians Society. Medical Cannabis Clinicians Society (cb1medical.com). bron
  553. Medical News Today (medisch beoordeeld) (2023). Rick Simpson oil for cancer: What is it, and does it work?. medicalnewstoday.com. bron
  554. Medisch Contact (redactie) (2023). Artsen schrijven minder vaak recept uit voor medicinale cannabis. medischcontact.nl. bron
  555. Medpets / NVWA-norm (2024). CBD olie bij huisdieren. Medpets.nl. bron
  556. Meerkosten.nl (Ieder(in) / kennisplatform) (2026). Medicijnen op voorschrift - aftrek zorgkosten. meerkosten.nl. bron
  557. Megelin T, Ghorayeb I (2017). Cannabis for restless legs syndrome: a report of six patients. Sleep Medicine. doi:10.1016/j.sleep.2017.04.019 bron
  558. Meier MH, Caspi A, Ambler A, et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences (PNAS). doi:10.1073/pnas.1206820109 bron
  559. Mendoza S. (2025). The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. AIMS Neuroscience. doi:10.3934/Neuroscience.2025003 bron
  560. Menezes IO, Scherf JR, Martins AO, Brito Pereira Bezerra Ramos AG, Barbosa Quintans JS, Siqueira Coutinho HD, Melo Ribeiro Filho J, Menezes IRA (2021). Biological properties of terpinolene evidenced by in silico, in vitro and in vivo tests: a systematic review. Phytomedicine. doi:10.1016/j.phymed.2021.153768 bron
  561. Merck Veterinary Manual (Sharon Gwaltney-Brant) (2024). Toxicosis in Dogs and Cats From Tetrahydrocannabinol (THC). Merck Veterinary Manual. bron
  562. Messineo L, Taranto-Montemurro L, Calianese N, Gell LK, Azarbarzin A, Labarca G, et al. (2023). The combination of atomoxetine and dronabinol for the treatment of obstructive sleep apnea: a dose-escalating, open-label trial. Journal of Clinical Sleep Medicine. doi:10.5664/jcsm.10528 bron
  563. Middelburg RA (2023). Medicinale cannabis. Geneesmiddelenbulletin (Ge-Bu). bron
  564. Millar SA, Stone NL, Bellman ZD, et al. (2019). A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology. doi:10.1111/bcp.14038 bron
  565. Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan SE (2019). A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology. doi:10.1111/bcp.14038 bron
  566. Millar SA, Stone NL, Yates AS, O'Sullivan SE (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Frontiers in Pharmacology. doi:10.3389/fphar.2018.01365 bron
  567. Ministère chargé de la Santé (Franse overheid) (2025). Therapeutic cannabis (Cannabis thérapeutique). service-public.gouv.fr. bron
  568. Ministerie van Buitenlandse Zaken, Nederland (2026). Reisadvies Thailand. NederlandWereldwijd. bron
  569. Ministerie van Justitie en Veiligheid (2017). Besluit alcohol, drugs en geneesmiddelen in het verkeer (artikel 3, grenswaarden). wetten.overheid.nl (BWBR0038936). bron
  570. Ministerie van Justitie en Veiligheid (2025). Experiment gesloten coffeeshopketen (wietexperiment). rijksoverheid.nl. bron
  571. Ministerie van Justitie en Veiligheid (2024). Besluit aanwijzing Halt-feiten 2024. Staatsblad van het Koninkrijk der Nederlanden, 2024-173. bron
  572. Ministerie van VWS (2013). Besluit houdende wijziging van lijst I, behorende bij de Opiumwet. officielebekendmakingen.nl. bron
  573. Ministerie van VWS (2021). Evaluatie Bureau voor medicinale cannabis. rijksoverheid.nl. bron
  574. Ministerie van VWS (2024). Opiumwet, Lijst I (hennepolie en tetrahydrocannabinol). wetten.overheid.nl (BWBR0001941). bron
  575. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering Myocardial Infarction by Marijuana. Circulation. doi:10.1161/01.CIR.103.23.2805 bron
  576. Miyazawa M, Yamafuji C (2005). Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids. Journal of Agricultural and Food Chemistry. bron
  577. Mlost J, Bryk M, Starowicz K (2020). Inhibitory Effect of Cannabidiol on the Activation of NLRP3 Inflammasome Is Associated with Its Modulation of the P2X7 Receptor in Human Monocytes. Journal of Natural Products. doi:10.1021/acs.jnatprod.0c00138 bron
  578. Moir D, Rickert WS, Levasseur G, et al. (2008). A Comparison of Mainstream and Sidestream Marijuana and Tobacco Cigarette Smoke Produced under Two Machine Smoking Conditions. Chemical Research in Toxicology. doi:10.1021/tx700275p bron
  579. Mojoli A, et al. (2025). Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial – CANOA. Frontiers in Pharmacology. doi:10.3389/fphar.2025.1657065 bron
  580. Monte AA, Shelton SK, Mills E, et al. (2019). Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Annals of Internal Medicine. doi:10.7326/M19-0542 bron
  581. Monte AA, Shelton SK, Mills E, et al. (2019). Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Annals of Internal Medicine 170(8):531-537. doi:10.7326/M18-2809 bron
  582. Morales P, Reggio PH (2017). Molecular Targets of the Phytocannabinoids: A Complex Picture. Progress in the Chemistry of Organic Natural Products. doi:10.1007/978-3-319-45541-9_4 bron
  583. Moreno-López N, Moreno-López C, Amariles P (2025). Cannabis-based products for medicinal use in dogs and cats: a systematic review. Journal of Small Animal Practice. doi:10.1111/jsap.13913 bron
  584. Moreno-Sanz G (2016). Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of Δ9-Tetrahydrocannabinolic Acid A. Cannabis and Cannabinoid Research. doi:10.1089/can.2016.0008 bron
  585. Morgan DJ, Davis BJ, Kearn CS, Marcus D, Cook AJ, Wager-Miller J, et al. (2014). Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. The Journal of Neuroscience. doi:10.1523/JNEUROSCI.3445-12.2014 bron
  586. Morrison G, Crockett J, Blakey G, Sommerville K (2019). A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects. Clinical Pharmacology in Drug Development. doi:10.1002/cpdd.665 bron
  587. Mosek A, Dano M, Fainmesser Y, Hybloom Z (2014). EHMTI-0136. Medical cannabis in the treatment of treatment-resistant, chronic cluster headache. A retrospective report. The Journal of Headache and Pain. doi:10.1186/1129-2377-15-S1-C46 bron
  588. Mosley PE, Webb L, Suraev A, et al. (2023). Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome. NEJM Evidence. doi:10.1056/EVIDoa2300012 bron
  589. Moura L, Costa J, Vaz-Carneiro A, et al. (2025). Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review. Biomolecules 15(6):816. doi:10.3390/biom15060816 bron
  590. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD012182.pub2 bron
  591. Mücke M, Weier M, Carter C, et al. (2018). Systematic review and meta-analysis of cannabinoids in palliative medicine. Journal of Cachexia, Sarcopenia and Muscle 9(2):220-234. doi:10.1002/jcsm.12273 bron
  592. Muller C, Morales P, Reggio PH (2019). Cannabinoid Ligands Targeting TRP Channels. Frontiers in Molecular Neuroscience. doi:10.3389/fnmol.2018.00487 bron
  593. Müller-Vahl KR, Pisarenko A, Fremer C, et al. (2023). CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Psychiatry Research. doi:10.1016/j.psychres.2023.115135 bron
  594. Müller-Vahl KR, Schneider U, Koblenz A, et al. (2002). Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. doi:10.1055/s-2002-25028 bron
  595. Müller-Vahl KR, Schneider U, Prevedel H, et al. (2003). Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. Journal of Clinical Psychiatry. doi:10.4088/jcp.v64n0417 bron
  596. Multidisciplinaire richtlijncommissie (2024). Preventie van valincidenten bij ouderen — Beoordeling valrisicoverhogende medicatie. Richtlijnendatabase.nl. bron
  597. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R (2019). Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretin-deficient Rats: Preliminary Data. CNS & Neurological Disorders – Drug Targets. doi:10.2174/1871527318666191029123existingformat bron
  598. Murni W, Umar TP, Tandarto K, Simatupang A, Hasugian AR, Purwoko RY, et al. (2023). Efficacy and safety of medical cannabinoids in children with cerebral palsy: a systematic review. einstein (São Paulo). doi:10.31744/einstein_journal/2023RW0387 bron
  599. Muzaffar A, et al. (2021). Clinical Investigation on the Impact of Cannabis Abuse on Thyroid Hormones and Associated Psychiatric Manifestations in the Male Population. Frontiers in Psychiatry. doi:10.3389/fpsyt.2021.730388 bron
  600. Myran DT, Harrison LD, Pugliese M, et al. (2024). Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study. eClinicalMedicine (The Lancet). doi:10.1016/j.eclinm.2024.102440 bron
  601. Nachnani R, et al. (2024). Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Frontiers in Pharmacology. doi:10.3389/fphar.2024.1282831 bron
  602. Nadal X, Del Río C, Casano S, et al. (2017). Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. British Journal of Pharmacology. doi:10.1111/bph.14019 bron
  603. Nadeem Z, Wu C, Burke S, Parker S (2023). Serotonin syndrome and cannabis: A case report. Australasian Psychiatry. doi:10.1177/10398562231219858 bron
  604. Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, et al. (2021). Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLOS ONE. doi:10.1371/journal.pone.0246871 bron
  605. Naftali T, Mechulam R, Marii A, et al. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. Digestive Diseases and Sciences. doi:10.1007/s10620-017-4540-z bron
  606. Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, Onoe K, Fukuda S, Kawabe J, Takahashi K, Kataoka Y, Shiomi S, Yamaguti K, Inaba M, Kuratsune H, Watanabe Y (2014). Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study. Journal of Nuclear Medicine. doi:10.2967/jnumed.113.131045 bron
  607. Narwani V, Bourdillon A, Nalamada K, Manes RP, Hildrew DM (2020). Does cannabis alleviate tinnitus? A review of the current literature. Laryngoscope Investigative Otolaryngology. doi:10.1002/lio2.479 bron
  608. Nasrin S, Watson CJW, Lazarus P, et al. (2024). Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metabolism and Disposition. doi:10.1124/dmd.123.001435 bron
  609. Nationaal Vergiftigingen Informatie Centrum (NVIC) / KNMvD (2024). NVIC-cijfers: gemelde intoxicaties bij mens en dier (2023). KNMvD.nl. bron
  610. Nationaal Vergiftigingen Informatie Centrum (UMC Utrecht) (2025). Drugs en illegale middelen - Jaarbeeld 2024. NVIC Jaarbeeld 2024, nvic.umcutrecht.nl. bron
  611. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. bron
  612. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press, Washington DC. doi:10.17226/24625 bron
  613. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. bron
  614. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. bron
  615. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press, Washington DC. bron
  616. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: Therapeutic Effects of Cannabis and Cannabinoids (Irritable Bowel Syndrome). National Academies Press / NCBI Bookshelf. bron
  617. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: Respiratory Disease (Chapter 7). National Academies Press / NCBI Bookshelf. bron
  618. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press, Washington DC. bron
  619. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press. bron
  620. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: Prenatal, Perinatal, and Neonatal Exposure to Cannabis. National Academies Press. bron
  621. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (hoofdstuk Mental Health). National Academies Press / NCBI Bookshelf. bron
  622. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press (NCBI Bookshelf). bron
  623. National Academies of Sciences, Engineering, and Medicine (NASEM) (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. bron
  624. National Academies of Sciences, Engineering, and Medicine (NASEM) (2017). Cannabis Use and the Abuse of Other Substances (Chapter 14). In: The Health Effects of Cannabis and Cannabinoids. National Academies Press / NCBI Bookshelf. bron
  625. National Academies of Sciences, Engineering, and Medicine (NASEM) (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. bron
  626. National Academies of Sciences, Engineering, and Medicine (NASEM) (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press / NCBI Bookshelf. bron
  627. National Academies of Sciences, Engineering, and Medicine (NASEM) (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press. bron
  628. National Cancer Institute (NCI), PDQ Integrative, Alternative, and Complementary Therapies Editorial Board (2026). Cannabis and Cannabinoids (PDQ) — Health Professional Version. National Cancer Institute (cancer.gov). bron
  629. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2023). Cannabidiol — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf / NIH. bron
  630. National Institute of Justice (Hall W. e.a., literatuuroverzicht) (2018). Is Cannabis a Gateway Drug? Key Findings and Literature Review. U.S. Department of Justice, Office of Justice Programs (NCJ 252950). bron
  631. National Institute on Drug Abuse (NIDA) (2024). Is marijuana addictive?. National Institutes of Health (NIH). bron
  632. Nationale Drug Monitor (Trimbos-instituut / WODC) (2024). Cannabis 3.7 Ziekte en sterfte — lichamelijke gezondheid (cannabinoïd hyperemesis syndroom). Nationale Drug Monitor. bron
  633. Nationale Drug Monitor (Trimbos-instituut / WODC) (2026). Wetgeving, beleid en preventie 2.1 Drugs (Opiumwetmiddelen). nationaledrugmonitor.nl. bron
  634. Nationale Drug Monitor (Trimbos-instituut & WODC) (actueel). Wetgeving, beleid en preventie — Medicinale cannabis. Nationale Drug Monitor (nationaledrugmonitor.nl). bron
  635. Nationale Politie (2024). U hebt thuis vijf hennepplanten of minder. politie.nl. bron
  636. Navarini L, et al. (2018). Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. International Journal of Biochemistry and Cell Biology. doi:10.1016/j.biocel.2018.04.007 bron
  637. Navarini L, Vomero M, Di Donato S, et al. (2022). 2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. Biomedicines. doi:10.3390/biomedicines10071675 bron
  638. Nederlands Huisartsen Genootschap (NHG) (2018). NHG-Standpunt Cannabis. Huisarts en Wetenschap / NHG. bron
  639. Nederlands Huisartsen Genootschap (NHG) (2023). Handreiking Proefbehandeling cannabis in de palliatieve fase voor huisartsen. nhg.org. bron
  640. Nederlands Huisartsen Genootschap (NHG) (2018). NHG-Standpunt Cannabis. Huisarts & Wetenschap (henw.org). bron
  641. Nederlands Huisartsen Genootschap (NHG) (2021). NHG-Standaard Hoofdpijn. NHG-Richtlijnen. bron
  642. Nederlands Huisartsen Genootschap (NHG) (2026). NHG-Standaard Dysmenorroe. NHG-Richtlijnen. bron
  643. Nederlandse Vereniging van Revalidatieartsen e.a. (2012). Richtlijn Amputatie en Prothesiologie Onderste Extremiteit — Behandeling fantoompijn na amputatie. Richtlijnendatabase.nl. bron
  644. Nederlandse Vereniging voor Fytotherapie (2023). CBD-olie en de wet. fyto.nl. bron
  645. Nederlandse Vereniging voor Neurologie (Richtlijnendatabase) (2023). Cannabidiol — Richtlijn Epilepsie. Richtlijnendatabase.nl. bron
  646. Nederlandse Vereniging voor Psychiatrie (NVvP) / CBR (2022). Richtlijn Onderzoek naar drugsmisbruik in het kader van rijgeschiktheidskeuringen (van kracht per 1 april 2022). Richtlijnendatabase.nl. bron
  647. Nederlandse Vereniging voor Reumatologie (NVR) / Federatie Medisch Specialisten (2022). Diagnostiek en behandeling van jicht in de 2e lijn. Richtlijnendatabase.nl. bron
  648. Nederlandse Vereniging voor Urologie (NVU) (2017). NVU Standpunt Blaaspijnsyndroom – diagnostiek en behandeling in Nederland (addendum EAU richtlijn chronische bekkenpijn). NVU / portal.nvu.nl. bron
  649. Nederlandse Voedsel- en Warenautoriteit (NVWA) (2026). Verbod op medische claims (voedings- en gezondheidsclaims). nvwa.nl. bron
  650. Nederlandse Voedsel- en Warenautoriteit (NVWA) (2024). Kwaliteitseisen voor cannabis in het Experiment Gesloten Coffeeshopketen. nvwa.nl. bron
  651. NeurologyLive (verslag CANALS-trial) (2018). Nabiximols Shows Improved Symptomatic Spasticity Control in ALS. NeurologyLive. bron
  652. Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA (2017). Subjective and Physiological Effects, and Expired Carbon Monoxide Concentrations in Frequent and Occasional Cannabis Smokers Following Smoked, Vaporized, and Oral Cannabis Administration. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2017.01.025 bron
  653. Ng JY, Gilotra K, Usman S, et al. (2022). The quality of health information provided on web sites selling cannabis to consumers in Canada is poor. BMC Complementary Medicine and Therapies. bron
  654. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ (2012). Beta-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a CNS region-dependent manner. Biological Psychiatry. doi:10.1016/j.biopsych.2011.10.012 bron
  655. NHS England (2025). Cannabis-based products for medicinal use (CBPMs). NHS England. bron
  656. Nielsen S, Sabioni P, Trigo JM, et al. (2017). Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology. doi:10.1038/npp.2017.51 bron
  657. Nivel (Nederlands instituut voor onderzoek van de gezondheidszorg) (2021). Weinig patiënten krijgen medicinale cannabis in de huisartsenpraktijk. nivel.nl. bron
  658. Noor A, Khalid S, Gilani SN, Hassan MS, Asghar MN (2024). Exploring the Therapeutic Potential of Terpenoids for Depression and Anxiety. Chemistry & Biodiversity 21(10):e202400788. doi:10.1002/cbdv.202400788 bron
  659. Noori A, Miroshnychenko A, Shergill Y, et al. (2021). Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. doi:10.1136/bmjopen-2020-047717 bron
  660. NORML (2016). Pharma Company Admits Opposing Marijuana Legalization to Protect Its Corporate Profits. NORML Blog. bron
  661. NOS (2019). Nederlandse mediwiet in trek: staat zoekt tweede producent. NOS Nieuws. bron
  662. NOS Redactie (2012). Wietpas per direct afgeschaft. NOS.nl. bron
  663. Novotna A, Mares J, Ratcliffe S, et al. (2011). A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology 18(9):1122-1131. bron
  664. NutraIngredients (W. Chu) (2026). EU continues CBD scrutiny, rejecting 6 more novel food applications. NutraIngredients Europe. bron
  665. Nuutinen T (2018). Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus. European Journal of Medicinal Chemistry. doi:10.1016/j.ejmech.2018.07.076 bron
  666. O'Neil ME, Nugent SM, Morasco BJ, et al. (2017). Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder: A Systematic Review. Annals of Internal Medicine. doi:10.7326/M17-0477 bron
  667. O'Sullivan SE (2016). An update on PPAR activation by cannabinoids. British Journal of Pharmacology. doi:10.1111/bph.13497 bron
  668. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proceedings of the National Academy of Sciences USA 103(3):696-701. doi:10.1073/pnas.0504187103 bron
  669. Office of Medicinal Cannabis (Bureau voor Medicinale Cannabis) (2025). Import and Export. english.cannabisbureau.nl (Rijksoverheid). bron
  670. Oh DA, Parikh N, Khurana V, Cognata Smith C, Vetticaden S (2017). Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clinical Pharmacology: Advances and Applications. doi:10.2147/CPAA.S119676 bron
  671. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllősi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Journal of Clinical Investigation 124(9):3713-3724. doi:10.1172/JCI64628 bron
  672. Olivier L, Giménez A, Andreu Gracia H, Bueno L, De Juan Viladegut O, Fernández TM, Ochandiano I, Salmerón S, Bracco L, Tardón Senabre L, Pacchiarotti I (2024). The role of cannabis in bipolar disorder relapse: a prospective study of hospital acute readmissions. European Psychiatry. doi:10.1192/j.eurpsy.2024.906 bron
  673. Onaivi ES, et al. (2014). Brain CB2 Receptors: Implications for Neuropsychiatric Disorders. PMC (review). bron
  674. Onderzoeksgroep King's College London (Translational Psychiatry) (2021). Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Translational Psychiatry. doi:10.1038/s41398-021-01330-w bron
  675. Oomen P, Rigter S (Trimbos-instituut) (2023). THC-concentraties in wiet, nederwiet en hasj (THC-monitor 2022-2023). trimbos.nl. bron
  676. Openbaar Ministerie (2015). Aanwijzing Opiumwet (2015A003). om.nl. bron
  677. Openbaar Ministerie (2024). Meer over medicijnen (verkeer, handhaving). om.nl. bron
  678. Openbaar Ministerie (2025). Richtlijn voor strafvordering Opiumwet, lijst I en lijst IA (2025R005). Openbaar Ministerie - Beleidsregels. bron
  679. Openbaar Ministerie (2023). Richtlijn voor strafvordering Opiumwet, softdrugs (2023R003). Openbaar Ministerie - Beleidsregels. bron
  680. Openbaar Ministerie (2021). Richtlijn en kader voor strafvordering jeugd en adolescenten, inclusief strafmaten Halt (2021R001). Openbaar Ministerie – Richtlijnen voor strafvordering. bron
  681. Openbaar Ministerie (2023). Richtlijn voor strafvordering Opiumwet, softdrugs (2023R003). Openbaar Ministerie – Richtlijnen voor strafvordering. bron
  682. Openbaar Ministerie / Overheid.nl (2026). Aanwijzing Opiumwet (BWBR0036356). wetten.overheid.nl. bron
  683. Outen JD, Burhanullah MH, Vandrey R, et al. (2021). Cannabinoids for Agitation in Alzheimer's Disease. The American Journal of Geriatric Psychiatry. doi:10.1016/j.jagp.2021.01.015 bron
  684. Overheid.nl (2026). Burgerlijk Wetboek art. 7:930 — Gevolgen niet-nakoming mededelingsplicht bij verzekering. wetten.overheid.nl. bron
  685. Overstappen.nl (2026). Vergoeding medicinale cannabis 2026. overstappen.nl. bron
  686. Pacheco-Colón, I., Limia, J.M., & Gonzalez, R. (2018). Nonacute effects of cannabis use on motivation and reward sensitivity in humans: A systematic review. Psychology of Addictive Behaviors. doi:10.1037/adb0000380 bron
  687. Pacheco-Colón, I., Ramírez, A.R., & Gonzalez, R. (2019). Effects of Adolescent Cannabis Use on Motivation and Depression: A Systematic Review. Current Addiction Reports. doi:10.1007/s40429-019-00274-y bron
  688. Page RL 2nd, Allen LA, Kloner RA, et al. (2020). Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. doi:10.1161/CIR.0000000000000883 bron
  689. Page RL 2nd, et al. (review) (2023). Cannabis and adverse cardiovascular events: A systematic review and meta-analysis of observational studies. PMC (peer-reviewed). bron
  690. Panlilio LV, Ferré S, Yasar S, Thorndike EB, Schindler CW, Goldberg SR (2012). Combined effects of THC and caffeine on working memory in rats. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2011.01554.x bron
  691. Papakyriakopoulou P, et al. (2026). Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks. British Journal of Clinical Pharmacology. doi:10.1002/bcp.70430 bron
  692. Park SY, An YS, Park SY (2021). Recent studies on pinene and its biological and pharmacological activities. EXCLI Journal. bron
  693. Parkinson.nl (Parkinson Vereniging) (2024). Medicinale cannabis. Parkinson.nl. bron
  694. Parrella NF, et al. (2026). Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial. Autism Research. doi:10.1002/aur.70159 bron
  695. Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A (2018). The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience and Biobehavioral Reviews 76(Pt A):56-66. doi:10.1016/j.neubiorev.2016.12.033 bron
  696. Patiëntenfederatie Nederland (2024). Vergoeding medicinale cannabis. patientenfederatie.nl (kennisbank). bron
  697. Patientengroep Medicinale Cannabisgebruikers (PGMCG) (2026). Vergoeding zorgverzekering Medicinale Cannabis 2026. pgmcg.nl. bron
  698. Patiëntenvereniging Gebruik Medicinale Cannabis en Gezondheid (PGMCG) (2025). Toelichting beschikbaar (Rijksoverheid) omtrent medicinale cannabis in het verkeer. PGMCG.nl. bron
  699. Payne KS, Mazur DJ, Hotaling JM, Pastuszak AW (2019). Cannabis and Male Fertility: A Systematic Review. Journal of Urology 202(3):674-681. doi:10.1097/JU.0000000000000248 bron
  700. Penner EA, Buettner H, Mittleman MA (2013). The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults. The American Journal of Medicine. doi:10.1016/j.amjmed.2013.03.002 bron
  701. Perry NS et al. (2000). In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. Journal of Pharmacy and Pharmacology. bron
  702. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology. doi:10.1038/sj.bjp.0707442 bron
  703. Pertwee RG (red.); Hanus LO e.a. (2022). Tribute to Professor Raphael Mechoulam, The Founder of Cannabinoid and Endocannabinoid Research. Molecules / PMC. doi:10.3390/molecules27010323 bron
  704. Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, Smoum R, Parker LA, Mechoulam R (2018). Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. British Journal of Pharmacology. doi:10.1111/bph.14073 bron
  705. Peskar D, Kerec Kos M, Tavčar Š, Lakota K, Kojc N, Veranič P, Erman A (2026). CBD Promotes Structural and Functional Epithelial Restoration and Alleviates Inflammation in a Mouse Model of Interstitial Cystitis. Pharmaceutics. doi:10.3390/pharmaceutics18040458 bron
  706. Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP (2022). Association of cannabis potency with mental ill health and addiction: a systematic review. The Lancet Psychiatry. doi:10.1016/S2215-0366(22)00161-4 bron
  707. Phan NQ, Siepmann D, Gralow I, Ständer S (2010). Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. Journal der Deutschen Dermatologischen Gesellschaft 8(2):88–91. doi:10.1111/j.1610-0387.2009.07213.x bron
  708. Piao JJ, Kim S, Lee HJ, Zhu GQ, Jeon KH, Park SH, Guan RL, Tian WJ, Xin ZC, Kim SW, Bae WJ (2025). Intravesical Cannabidiol for Inflammation and Pain in Interstitial Cystitis/Bladder Pain Syndrome via TLR4/NF-κB and TRPV1 Modulation. World Journal of Men's Health. doi:10.5534/wjmh.250152 bron
  709. Picavet, M. (2020). Nee, er komt geen 'staatswiet' of max 15% THC in de wietproef. CannabisIndustrie.nl. bron
  710. Pinto JV, Crippa JAS, Ceresér KM, Vianna-Sulzbach MF, Silveira Júnior EM, da Rosa GS, Testa da Silva MG, Hizo GH, Medeiros LS, Santana de Oliveira CE, Bristot G, Campos AC, et al. (2024). Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study. Canadian Journal of Psychiatry. doi:10.1177/07067437231209650 bron
  711. Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ (2023). Mechanisms of cannabinoid tolerance. Biochemical Pharmacology. doi:10.1016/j.bcp.2023.115665 bron
  712. Pletcher MJ, Vittinghoff E, Kalhan R, et al. (2012). Association Between Marijuana Exposure and Pulmonary Function Over 20 Years (CARDIA Study). JAMA. doi:10.1001/jama.2011.1961 bron
  713. Poulsen LK, et al. (2025). Gout and NLRP3 Inflammasome Biology. Arthritis & Rheumatology. doi:10.1002/art.43215 bron
  714. Poyatos L, Pérez-Acevedo AP, Papaseit E, Pérez-Mañá C, Martin S, Hladun O, Siles A, Torrens M, Busardò FP, Farré M (2020). Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina. doi:10.3390/medicina56060309 bron
  715. Pray IW, Atti SK, Tomasallo C, Meiman JG (2020). E-cigarette, or Vaping, Product Use-Associated Lung Injury Among Clusters of Patients Reporting Shared Product Use - Wisconsin, 2019. MMWR Morbidity and Mortality Weekly Report 69(9):236-240, CDC. bron
  716. Price RL, Charlot KV, Frieler S, Dettori JR, Oskouian R, Chapman JR (2022). The Efficacy of Cannabis in Reducing Back Pain: A Systematic Review. Global Spine Journal. doi:10.1177/21925682211065411 bron
  717. Procopio AC, et al. (2025). Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. Frontiers in Pharmacology. doi:10.3389/fphar.2025.1561385 bron
  718. Prohibition Partners (2025). Netherlands Medical Cannabis Market Overview 2025. Prohibition Partners. bron
  719. Project CBD (Adrian Devitt-Lee / interview ElSohly, Hergenrather) (2020). Do Cannabis Suppositories Work?. Project CBD. bron
  720. Quest Diagnostics (2024). Specimen Validity Testing. Quest Diagnostics (employer drug screening). bron
  721. Radparvar S (2024). Clinical Evaluation of the Cannabis-Using Patient: A Moving Target. The Permanente Journal. doi:10.7812/TPP/24.088 bron
  722. Rakotoarivelo V, Mayer TZ, Simard M, Flamand N, Di Marzo V (2024). The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update. Molecules. doi:10.3390/molecules29143381 bron
  723. Ramar K, Rosen IM, Kirsch DB, Chervin RD, Carden KA, Aurora RN, et al.; American Academy of Sleep Medicine Board of Directors (2018). Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement. Journal of Clinical Sleep Medicine. doi:10.5664/jcsm.7070 bron
  724. Rao A, Briskey D, Nalley JO, et al. (2024). Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial. Skin Pharmacology and Physiology. doi:10.1159/000536670 bron
  725. Ray EJ, et al. (2022). Delta-8 Tetrahydrocannabinol Product Impurities. Molecules. doi:10.3390/molecules27206924 bron
  726. Rechtbank 's-Gravenhage (2012). Verzwijging drugsgebruik (cannabis, cocaïne) tijdens studietijd aangemerkt als opzet tot misleiding; volgt afwijzing AOV-claim. Arbeidsongeschiktheidsmagazine.nl / rechtspraak.nl. bron
  727. Rechtbank Zeeland-West-Brabant (RBOBR) (2025). Onterechte beëindiging AOV vanwege drugsgebruik in het verleden; onterechte weigering uitkering. LSA Letselschade Magazine / rechtspraak.nl. bron
  728. Redactie NTVG (2002). Fantoompijn en andere fantoomverschijnselen na amputatie. Nederlands Tijdschrift voor Geneeskunde. bron
  729. Redonnet B, et al. (2025). Efficacy of cannabidiol alone or in combination with delta-9-tetrahydrocannabinol for the management of substance use disorders: an umbrella review of the evidence. Addiction. doi:10.1111/add.16745 bron
  730. Releaf UK (redactie) (2025). Travel Tuesday: Taking medical cannabis to Spain. releaf.co.uk. bron
  731. Rey AA, Purrio M, Viveros MP, Lutz B (2012). Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology. doi:10.1038/npp.2012.123 bron
  732. Reyes Orozco F, Lin M, et al. (2023). Association between Cannabis Use and Tinnitus in US Adults. Otology & Neurotology. doi:10.1097/MAO.0000000000003895 bron
  733. Ribeiro LIG, Ind PW (2016). Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. npj Primary Care Respiratory Medicine. doi:10.1038/npjpcrm.2016.71 bron
  734. Ridout KK, Young-Wolff KC, Ridout SJ (2021). A Change in Blood Carbamazepine Levels Associated With Cannabis Use: Implications for Clinical Practice. Journal of Clinical Psychiatry 82(3):20cr13777. doi:10.4088/JCP.20cr13777 bron
  735. Rijksoverheid (2025). Wat heb ik nodig als ik mijn medicijnen meeneem op reis? (verklaring voor medicijnen Opiumwet). rijksoverheid.nl. bron
  736. Rijksoverheid (2025). Experiment gesloten coffeeshopketen (wietexperiment). rijksoverheid.nl. bron
  737. Rijksoverheid (2024). Wat is het verschil tussen cannabis, wiet, hennep of hasjiesj?. rijksoverheid.nl. bron
  738. Rijksoverheid (2025). Klachten en geschillen over vergoeding (Zvw). zorginstituutnederland.nl. bron
  739. Rijksoverheid (2025). Krijg ik een boete voor medicijngebruik in het verkeer?. rijksoverheid.nl. bron
  740. Rijksoverheid (2025). Mag ik deelnemen aan het verkeer als ik medicijnen heb gebruikt?. rijksoverheid.nl. bron
  741. Rijksoverheid (2026). Gedoogbeleid softdrugs en coffeeshops. rijksoverheid.nl. bron
  742. Rijksoverheid (2026). Wet maakt verschil tussen harddrugs en softdrugs. rijksoverheid.nl. bron
  743. Rijksoverheid (2025). Experiment gesloten coffeeshopketen (wietexperiment) - deelnemende gemeenten. rijksoverheid.nl. bron
  744. Rijksoverheid (2024). Straffen en maatregelen voor jongeren. Rijksoverheid.nl. bron
  745. Rijksoverheid (Ministerie van VWS en JenV) (2026). Deelnemende gemeenten wietexperiment. Rijksoverheid.nl. bron
  746. Rijksoverheid (Ministerie van VWS en JenV) (2026). Aanleiding en opzet experiment gesloten coffeeshopketen. Rijksoverheid.nl. bron
  747. Rijksoverheid (Ministerie van VWS en JenV) (2026). Tijdlijn experiment gesloten coffeeshopketen. Rijksoverheid.nl. bron
  748. Rijksoverheid / Bureau voor Medicinale Cannabis (2025). Bureau voor Medicinale Cannabis (BMC). Rijksoverheid.nl. bron
  749. Rijksoverheid, Ministerie van VWS (2024). Hoe krijg ik een second opinion in de zorg?. rijksoverheid.nl. bron
  750. Rijksoverheid, Ministerie van VWS (2024). Rechten en plichten bij een medische behandeling. rijksoverheid.nl. bron
  751. Rijksoverheid, Ministerie van VWS (2024). Wet kwaliteit, klachten en geschillen zorg (Wkkgz). rijksoverheid.nl. bron
  752. Rijksoverheid, Nederland (2025). Welk risico loop ik als ik drugs meeneem naar het buitenland?. Rijksoverheid.nl. bron
  753. Riney Canine Health Center, Cornell University College of Veterinary Medicine (2023). Cannabis (THC) intoxication in dogs. Cornell University College of Veterinary Medicine. bron
  754. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T (2025). High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes: A Systematic Review. Annals of Internal Medicine. doi:10.7326/ANNALS-24-03819 bron
  755. Riva N, Mora G, Sorarù G, et al. (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. doi:10.1016/S1474-4422(18)30406-X bron
  756. Rivas da Silva AC et al. (2012). Biological activities of α-pinene and β-pinene enantiomers. Molecules. doi:10.3390/molecules17066305 bron
  757. RIVM (2016). Cannabis contaminanten (Briefrapport 2015-0205). RIVM Briefrapport. bron
  758. RIVM (Rijksinstituut voor Volksgezondheid en Milieu) (2016). Cannabis contaminanten. rivm.nl. bron
  759. Robert M, Graves LE, Allen VM, Dama S, Gabrys RL, Tanguay RL, Turner SD, Green CR, Cook JL (2022). Guideline No. 425a: Cannabis Use Throughout Women's Lifespans – Part 1: Fertility, Contraception, Menopause, and Pelvic Pain. Journal of Obstetrics and Gynaecology Canada. doi:10.1016/j.jogc.2022.01.012 bron
  760. Robertson R, et al. (2026). High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. eClinicalMedicine. bron
  761. Robinson T, Ali MU, Easterbrook B, et al. (2022). Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychological Medicine. doi:10.1017/S0033291722000502 bron
  762. Rock EM, Limebeer CL, Pertwee RG, Mechoulam R, Parker LA (2021). Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting. Cannabis and Cannabinoid Research. doi:10.1089/can.2021.0041 bron
  763. Rock EM, Sullivan MT, Pravato S, Pratt M, Limebeer CL, Parker LA (2020). Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. Psychopharmacology. doi:10.1007/s00213-020-05559-z bron
  764. Rodríguez-Ramírez S, Gaber AO, Suki WN, Elghar H, Jeroudi M, Graviss EA, Gaber OA (2024). Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post-transplant. Clinical Transplantation. doi:10.1111/ctr.15264 bron
  765. Rogeberg O (2013). Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. PNAS. doi:10.1073/pnas.1215678110 bron
  766. Rogeberg O, Elvik R (2016). The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction 111(8):1348-1359. doi:10.1111/add.13347 bron
  767. Rogerio AP, Andrade EL, Leite DF, et al. (2009). Preventive and therapeutic anti-inflammatory properties of the sesquiterpene alpha-humulene in experimental airways allergic inflammation. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2009.00369.x bron
  768. Rogers CI, Pacanowski CR (2023). The relationship between cannabis and anorexia nervosa: a scoping review. Journal of Eating Disorders. doi:10.1186/s40337-023-00887-9 bron
  769. Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio MG, Pertwee RG, Coppola D, Vassallo L, Orlando P, Di Marzo V, Izzo AA (2013). The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. British Journal of Pharmacology. doi:10.1111/bph.12120 bron
  770. Romano GL et al. (2025). Role of the Endocannabinoid System in Fibromyalgia. Current Issues in Molecular Biology. bron
  771. Rosenberg MJ, Waugh MS, Stevens CM (1996). Smoking and cycle control among oral contraceptive users. American Journal of Obstetrics and Gynecology. doi:10.1016/S0002-9378(96)70440-4 bron
  772. RTV Maastricht (redactie) (2025). Handhaving op verkoop illegale hasj opnieuw uitgesteld. rtvmaastricht.nl. bron
  773. Rubio-Tapia A, McCallum R, Camilleri M (2024). AGA Clinical Practice Update on Diagnosis and Management of Cannabinoid Hyperemesis Syndrome: Commentary. Gastroenterology. doi:10.1053/j.gastro.2024.01.040 bron
  774. Ruchlemer R, Amit-Kohn M, Raveh D, Hanuš L (2015). Inhaled medicinal cannabis and the immunocompromised patient. Supportive Care in Cancer. doi:10.1007/s00520-014-2429-3 bron
  775. Rup J, Freeman TP, Perlman C, Hammond D (2021). A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. The American Journal of Drug and Alcohol Abuse. doi:10.1080/00952990.2021.1946071 bron
  776. Russo EB (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. doi:10.1111/j.1476-5381.2011.01238.x bron
  777. Russo EB (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research. doi:10.1089/can.2016.0009 bron
  778. Russo EB (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuroendocrinology Letters. bron
  779. Ryan JE, Herens A, Fruchtman M, Veliz P, Kelly EL, Worster B (2026). Cannabis Use in a Community-Based Sample of Adults Diagnosed With ADHD: Prevalence, Impact on Symptoms, and Stimulant Side Effects. Journal of Attention Disorders. bron
  780. Ryberg E, Larsson N, Sjögren S, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology. doi:10.1038/sj.bjp.0707460 bron
  781. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. (2009). Interindividual variation in the pharmacokinetics of Δ9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clinical Pharmacology & Therapeutics. bron
  782. Sahota P et al. (2026). Cannabidiol in Anorexia Nervosa: A Double-Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change. International Journal of Eating Disorders. doi:10.1002/eat.70034 bron
  783. Sainsbury B, et al. (2021). Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PLOS ONE / PMC. doi:10.1371/journal.pone.0280675 bron
  784. Salehi B et al. (2019). Therapeutic Potential of α- and β-Pinene: A Miracle Gift of Nature. Biomolecules. doi:10.3390/biom9110738 bron
  785. Sanchez AM, Vigano P, Mugione A, Panina-Bordignon P, Candiani M (2016). The Clinical Significance of Endocannabinoids in Endometriosis Pain Management. Cannabis and Cannabinoid Research. doi:10.1089/can.2016.0035 bron
  786. Sarchielli P et al. (2007). Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System Failure. Neuropsychopharmacology. doi:10.1038/sj.npp.1301246 bron
  787. Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, Cozzi NV, D'Souza DC (2024). Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal of the Neurological Sciences. doi:10.1016/j.jns.2024.122993 bron
  788. Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, Lindsey H, Pittman BP, Cozzi NV, D'Souza DC (2022). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. Headache: The Journal of Head and Face Pain. doi:10.1111/head.14420 bron
  789. Scholfield CN, Waranuch N, Kongkaew C (2023). Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. Cannabis and Cannabinoid Research. doi:10.1089/can.2021.0154 bron
  790. Scholten WK (2006). Het werkingsmechanisme van cannabis en cannabinoïden. Nederlands Tijdschrift voor Geneeskunde (Ned Tijdschr Geneeskd 2006;150:128-31). bron
  791. Schünemann HJ, Higgins JPT, Vist GE, et al. (Cochrane) (2024). Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. Cochrane Handbook for Systematic Reviews of Interventions. bron
  792. Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L, Sexton M (2026). Vaporized cannabis versus placebo for acute migraine: a randomized, double-blind, placebo-controlled crossover trial. Headache: The Journal of Head and Face Pain. doi:10.1111/head.70025 bron
  793. Schwilke EW, Gullberg RG, Darwin WD, et al. (2011). Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction. doi:10.1111/j.1360-0443.2010.03228.x bron
  794. Schwilke EW, Gullberg RG, Darwin WD, et al. (2011). Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. Journal of Analytical Toxicology. doi:10.1093/jat/35.8.500 bron
  795. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA (2009). Delta9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC, and 11-Nor-9-carboxy-THC Plasma Pharmacokinetics during and after Continuous High-Dose Oral THC. Clinical Chemistry. doi:10.1373/clinchem.2008.122119 bron
  796. Scott C, Hall S, Zhou J, Lehmann C (2024). Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19: A Scoping Review. Journal of Clinical Medicine. doi:10.3390/jcm13010227 bron
  797. Scott JC, Slomiak ST, Jones JD, et al. (2018). Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2018.0335 bron
  798. Sebastian SA, Shah Y, Arsene C, Krishnamoorthy G (2025). Cannabis use and atherosclerotic cardiovascular disease outcomes: A meta-analysis of multinational cohort data. Disease-a-Month. doi:10.1016/j.disamonth.2024.101849 bron
  799. Seevathee K, Kessomboon P, Manimmanakorn N, Luangphimai S, Thaneerat T, Wanaratna K, Plengphanich S, Thaenkham T, Sena W (2024). Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities. Medical Cannabis and Cannabinoids. doi:10.1159/000550537 bron
  800. Seifalian A, Kenyon J, Khullar V (2022). Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?. International Journal of Molecular Sciences 23(24):16201. doi:10.3390/ijms232416201 bron
  801. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S (2010). Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor. Diabetes Care. bron
  802. Sepulveda DE, Vrana KE, Graziane NM, Raup-Konsavage WM (2024). The Potential of Cannabichromene (CBC) as a Therapeutic Agent. Journal of Pharmacology and Experimental Therapeutics. doi:10.1124/jpet.124.002166 bron
  803. Service Apotheek (2025). Medicijnen meenemen naar het buitenland. serviceapotheek.nl. bron
  804. Sexton M, Schuster N (2024). Cannabinoids and Psychedelics for Headache Management. Practical Neurology. bron
  805. Shah S, Schwenk ES, Narouze S. (2023). ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids: an infographic. Regional Anesthesia & Pain Medicine 48(3):119. doi:10.1136/rapm-2022-104193 bron
  806. Shah S, Schwenk ES, Sondekoppam RV, et al. (2023). ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Regional Anesthesia & Pain Medicine 48(3):97-117. doi:10.1136/rapm-2022-104013 bron
  807. Sharir H, Abood ME (2010). Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacology & Therapeutics. doi:10.1016/j.pharmthera.2010.02.004 bron
  808. Sharma P, Murthy P, Bharath MMS (2012). Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications. Iranian Journal of Psychiatry. bron
  809. Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J (2020). Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal of Translational Medicine. doi:10.1186/s12967-020-02518-2 bron
  810. Shen X, Duan H, Wang S, Hong W, Wang YY, Lin SL (2019). Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. Reproductive Sciences 26(9):1222–1230. doi:10.1177/1933719119833483 bron
  811. Sherman JJ, Riche DM (2026). Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review. Cannabis and Cannabinoid Research. doi:10.1177/25785125261425444 bron
  812. Sherpa ML, Shrestha N, Ojinna BT, et al. (2022). Efficacy and Safety of Medical Marijuana in Migraine Headache: A Systematic Review. Cureus. doi:10.7759/cureus.32622 bron
  813. Shi S, Brant AR, Sabolch A, Pollom E (2019). False News of a Cannabis Cancer Cure. Cureus 11(1):e3918. doi:10.7759/cureus.3918 bron
  814. Shustorovich A, Corroon J, Wallace MS, Sexton M (2024). Biphasic effects of cannabis and cannabinoid therapy on pain severity, anxiety, and sleep disturbance: a scoping review. Pain Medicine. doi:10.1093/pm/pnae004 bron
  815. Siebers M, Biedermann SV, Bindila L, Lutz B, Fuss J (2021). Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. Psychoneuroendocrinology. doi:10.1016/j.psyneuen.2021.105173 bron
  816. Siebers M, Biedermann SV, Fuss J (2023). Do Endocannabinoids Cause the Runner's High? Evidence and Open Questions. The Neuroscientist. doi:10.1177/10738584211069981 bron
  817. Siegel DA, Jatlaoui TC, Koumans EH, et al. (2019). Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected EVALI - United States, October 2019. MMWR Morbidity and Mortality Weekly Report 2019;68:919-927. doi:10.15585/mmwr.mm6841e3 bron
  818. Simon L, Baldwin C, Kalea AZ, Slee A (2021). Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. doi:10.1002/jcsm.12861 bron
  819. Sinclair J, Collett L, Abbott J, Pate DW, Sarris J, Armour M (2021). Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. PLOS ONE. doi:10.1371/journal.pone.0258940 bron
  820. Singh RK, Dillon B, Tatum DA, Van Poppel KC, Bonthius DJ (2020). Drug-Drug Interactions Between Cannabidiol and Lithium. Child Neurology Open. doi:10.1177/2329048X20947896 bron
  821. Singh SK, et al. (2026). Therapeutic potential of acidic cannabinoids: an update. Journal of Cannabis Research. doi:10.1186/s42238-026-00387-y bron
  822. Skolnick P, Crystal R (2019). Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose. Journal of Neural Transmission. doi:10.1007/s00702-019-02132-7 bron
  823. Skumlien, M., Mokrysz, C., Freeman, T.P., Valton, V., Wall, M.B., Bloomfield, M., Lees, R., Borissova, A., Petrilli, K., Giugliano, M., Clisu, D., Langley, C., Sahakian, B.J., Curran, H.V., & Lawn, W. (2023). Anhedonia, Apathy, Pleasure, and Effort-Based Decision-Making in Adult and Adolescent Cannabis Users and Controls. International Journal of Neuropsychopharmacology. doi:10.1093/ijnp/pyac056 bron
  824. Skypala IJ, Jeimy S, Brucker H, Ellis AK, Silvers WS, Ebo DG, et al. (2022). Cannabis-related allergies: An international overview and consensus recommendations. Allergy. doi:10.1111/all.15237 bron
  825. Slijkhuis C, Hoving R, Blok-Tip L, de Kaste D (2004). Kwaliteitsnormen Medicinale Cannabis. RIVM Rapport 267011001/2004. bron
  826. Smith CJ, Vergara D, Keegan B, Jikomes N (2022). The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. doi:10.1371/journal.pone.0267498 bron
  827. Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database of Systematic Reviews, Issue 11, CD009464. doi:10.1002/14651858.CD009464.pub2 bron
  828. Smith PF, Zheng Y (2019). Cannabinoid drugs: will they relieve or exacerbate tinnitus?. Current Opinion in Neurology. doi:10.1097/WCO.0000000000000633 bron
  829. Smythe MA, Wu W, Garwood CL (2023). Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. doi:10.1002/phar.2881 bron
  830. So GC, et al. (2025). A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus. Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.3504 bron
  831. So GC, et al. (2025). Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro. Clinical and Translational Science. doi:10.1111/cts.70152 bron
  832. Society of Cannabis Clinicians (2025). Aspergillus in Cannabis: Evaluating the Evidence and Crafting Sensible Policies. cannabisclinicians.org. bron
  833. Sokolaj E, Assareh N, Anderson K, Aubrey KR, Vaughan CW (2024). Cannabis constituents for chronic neuropathic pain; reconciling the clinical and animal evidence. Journal of Neurochemistry. doi:10.1111/jnc.15964 bron
  834. Sophocleous A, Robertson R, Ferreira NB, McKenzie J, Fraser WD, Ralston SH (2017). Heavy Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of Fractures. The American Journal of Medicine 130(2):214-221. doi:10.1016/j.amjmed.2016.07.033 bron
  835. Sophocleous A, Yiallourides M, Zeng Z, Pantelas A, Stylianou P, Li L, Carrasco C, Idris AI (2021). Association of cannabinoid receptor modulation with normal and abnormal skeletal remodelling: A systematic review and meta-analysis of in vitro, in vivo and human studies. Pharmacology Research 174:105928. doi:10.1016/j.phrs.2021.105928 bron
  836. Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA (2017). Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review. Journal of Medical Toxicology. doi:10.1007/s13181-016-0595-z bron
  837. Sorkhou M, Dent EL, George TP (2024). Cannabis use and mood disorders: a systematic review. Frontiers in Public Health. doi:10.3389/fpubh.2024.1346207 bron
  838. Sousa VC, Assaife-Lopes N, Ribeiro JA, Pratt JA, Brett RR, Sebastião AM (2011). Regulation of Hippocampal Cannabinoid CB1 Receptor Actions by Adenosine A1 Receptors and Chronic Caffeine Administration: Implications for the Effects of Δ9-Tetrahydrocannabinol on Spatial Memory. Neuropsychopharmacology. doi:10.1038/npp.2010.179 bron
  839. Sousa VC, Ribeiro JA, Sebastião AM (2013). Caffeine and Adenosine Receptor Modulation of Cannabinoid Influence Upon Cognitive Function. Journal of Caffeine Research. doi:10.1089/jcr.2013.0010 bron
  840. Souza JDR, Pacheco JC, Rossi GN, De-Paulo BO, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA, Dos Santos RG (2022). Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14(12):2598. doi:10.3390/pharmaceutics14122598 bron
  841. Spiga F, Parkhouse T, Tang VM, Savovic J, Le Foll B, Nielsen S (2025). Pharmacotherapies for cannabis use disorder. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008940.pub4 bron
  842. Spindle TR, Cone EJ, Kuntz D, Mitchell JM, Bigelow GE, Flegel R, Vandrey R (2020). Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis. Journal of Analytical Toxicology 44(2):109-125. doi:10.1093/jat/bkz080 bron
  843. Spindle TR, Cone EJ, Schlienz NJ, et al. (2019). Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. Journal of Analytical Toxicology. doi:10.1093/jat/bky104 bron
  844. Spindle TR, et al. / Johns Hopkins Medicine (2019). Some CBD Products May Yield Cannabis-Positive Urine Drug Tests. Johns Hopkins Medicine Newsroom. bron
  845. Spindle TR, Sholler DJ, Cone EJ, et al. (2022). Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores. JAMA Network Open. doi:10.1001/jamanetworkopen.2022.23019 bron
  846. Spindle TR, Zamarripa CA, Russo EB, et al. (2024). Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Delta-9-tetrahydrocannabinol in healthy adults who intermittently use cannabis. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2024.111267 bron
  847. Staat der Nederlanden (2020). Besluit experiment gesloten coffeeshopketen (BWBR0043738). wetten.overheid.nl. bron
  848. Staat der Nederlanden (1928). Opiumwet (geconsolideerde tekst, met Lijst I en Lijst II). wetten.overheid.nl. bron
  849. Staat der Nederlanden (2017). Regeling alcohol, drugs en geneesmiddelen in het verkeer (BWBR0039687). wetten.overheid.nl. bron
  850. Staat der Nederlanden (Ministerie van VWS) (2026). Besluit tot wijziging van lijst I en lijst II behorende bij de Opiumwet (plaatsing van o.a. HHC op lijst I). Staatsblad 2026, nr. 11. bron
  851. Stanciu CN, Brunette MF, Teja N, Budney AJ (2021). Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review. Psychiatric Services. doi:10.1176/appi.ps.202000189 bron
  852. Starkey B, Pearlson GD, Bond D, Glaser C, Bhargava A, Grosberg BM, Verhaak A (2024). Characterizing Cannabis Use and Perceived Benefit in a Tertiary Headache Center Patient Sample. Neurology Clinical Practice. doi:10.1212/CPJ.0000000000200285 bron
  853. Stefanović M, Osredkar D, Rener-Primec Z, Peterlin J, Laptoš T, Neubauer D (2024). Plant-derived cannabinoids for treatment of spasticity in children and adolescents with severe cerebral palsy: Double-blind, placebo-controlled trial. European Journal of Paediatric Neurology. doi:10.1016/j.ejpn.2024.11.007 bron
  854. Stichting ADHD Netwerk (2023). Medicinale cannabis voor ADHD?. ADHD Netwerk kennisbank. bron
  855. Stichting Klachten en Geschillen Zorgverzekeringen (SKGZ) (2025). Vraag en antwoord - klacht indienen. skgz.nl. bron
  856. Stichting School en Veiligheid (2024). Controle op verboden spullen op school. Schoolenveiligheid.nl. bron
  857. Stichting Werkgroep Antibiotica Beleid (SWAB) (2023). Advies diagnostiek en profylaxe ter voorkoming van invasieve aspergillose bij volwassen patiënten. SWAB / swab.nl. bron
  858. Stith SS, Li X, Brockelman F, Keeling K, Hall B, Vigil JM (2025). Cannabis tolerance reduces symptom relief. Frontiers in Pharmacology. doi:10.3389/fphar.2025.1496232 bron
  859. Stoner SA (review of recent findings) (2023). THC, CBD, and Anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis' primary cannabinoids. PMC (review article). bron
  860. Storck W, et al. (2025). Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart. doi:10.1136/heartjnl-2024-325429 bron
  861. Stott C, White L, Wright S, Wilbraham D, Guy G (2013). A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. SpringerPlus. doi:10.1186/2193-1801-2-236 bron
  862. Stover J, Sabol VK, Eastman A, Simmons VC. (2023). Preoperative preparation and guidelines for cannabis-using patients undergoing elective surgery. Journal of PeriAnesthesia Nursing 38(4):560-563. doi:10.1016/j.jopan.2022.10.002 bron
  863. Strand NH, Maloney J, Kraus M, et al. (2023). Cannabis for the Treatment of Fibromyalgia: A Systematic Review. Biomedicines. doi:10.3390/biomedicines11061621 bron
  864. Strickland JC, Tilton HE, Patton NM, Vandrey R, Zamarripa CA, Spindle TR, Lee DC, Bergeria CL, Wolinsky D, Klawitter J, Sempio C, Campos-Palomino J, Christians U, Feldner MT, Irons JG, Bonn-Miller MO (2025). Effect of caffeine and cannabidiol (CBD) co-administration on Δ9-tetrahydrocannabinol (Δ9-THC) subjective effects, performance impairment, and pharmacokinetics. Neuropsychopharmacology. doi:10.1038/s41386-025-02232-x bron
  865. Stueber A, Cuttler C (2022). Self-Reported Effects of Cannabis on ADHD Symptoms, ADHD Medication Side Effects, and ADHD-Related Executive Dysfunction. Journal of Attention Disorders. bron
  866. Suraev A, Lavender IG, Hoyos CM, et al. (2026). Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. Journal of Sleep Research. doi:10.1111/jsr.70124 bron
  867. Suzuki S, Wakano C, Monteilh-Zoller MK, Cullen AJ, Fleig A, Penner R (2024). Cannabigerolic Acid (CBGA) Inhibits the TRPM7 Ion Channel Through its Kinase Domain. Function. doi:10.1093/function/zqad069 bron
  868. SWOV - Instituut voor Wetenschappelijk Onderzoek Verkeersveiligheid (2023). Geneesmiddelen en drugs in het Nederlandse verkeer. swov.nl. bron
  869. Szejko N, Fremer C, Muller-Vahl KR (2020). Cannabis Improves Obsessive-Compulsive Disorder - Case Report and Review of the Literature. Frontiers in Psychiatry. doi:10.3389/fpsyt.2020.00681 bron
  870. Sznitman SR, et al. (2025). Medical cannabis in Israel: a comprehensive review of trends and regulations, 2011-2025. Journal of Cannabis Research. doi:10.1186/s42238-025-00344-1 bron
  871. T.M.C. Asser Instituut / WODC (2014). Internationaal recht en cannabis. Tweedekamer.nl / WODC. bron
  872. Tagen M, Klumpers LE (2022). Review of delta-8-tetrahydrocannabinol (Δ8-THC): Comparative pharmacology with Δ9-THC. British Journal of Pharmacology. doi:10.1111/bph.15865 bron
  873. Tahir MN, Shahbazi Raz F, Rondeau-Gagné S, Trant JF (2021). The biosynthesis of the cannabinoids. Journal of Cannabis Research. doi:10.1186/s42238-021-00062-4 bron
  874. Takeda S, Misawa K, Yamamoto I, Watanabe K (2008). Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metabolism and Disposition. doi:10.1124/dmd.108.020909 bron
  875. Tan WC, Lo C, Jong A, et al. (2009). Marijuana and chronic obstructive lung disease: a population-based study. CMAJ. bron
  876. Tarlovski T, et al. (2024). Comparative Pharmacokinetic Assessment of Innovative Sublingual, Rectal and Vaporizer Cannabis Products Versus Approved Cannabis Products in Healthy Volunteers. Cannabis and Cannabinoid Research. doi:10.1089/can.2023.0229 bron
  877. Tashkin DP, Shapiro BJ, Frank IM (1974). Acute effects of smoked marijuana and oral delta-9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. American Review of Respiratory Disease. doi:10.1164/arrd.1974.109.4.420 bron
  878. Terms.Law Editorial (2026). Thailand Cannabis Laws 2026: What's Actually Legal Now. Terms.Law. bron
  879. Tewari D, et al. (2023). The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD. Inflammation Research. doi:10.1007/s00011-023-01831-y bron
  880. Thanabalasingam SJ, Ranjith B, Jackson R, Wijeratne DT (2021). Cannabis and its derivatives for the use of motor symptoms in Parkinson's disease: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders. doi:10.1177/17562864211018561 bron
  881. The Cannigma (2026). Cannabis Laws in China: Penalties, CBD & Border Testing. The Cannigma. bron
  882. The Public Domain Review (2019). W. B. O'Shaughnessy and the Introduction of Cannabis to Modern Western Medicine. The Public Domain Review. bron
  883. The Sports Integrity Initiative (2021). Athletes serving bans for a 'substance of abuse' can apply for a reduction. sportsintegrityinitiative.com. bron
  884. Therapeutic Goods Administration (TGA) (2025). Medicinal cannabis: access pathways and usage data. Australian Government, TGA. bron
  885. Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJK, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group (2022). Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. Epilepsia. bron
  886. Thiele EA, Bebin EM, Filloux F, et al. (2021). Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial (GWPCARE6). JAMA Neurology. doi:10.1001/jamaneurol.2020.4607 bron
  887. Thiele EA, Marsh ED, French JA, et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. doi:10.1016/S0140-6736(18)30136-3 bron
  888. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG (2005). Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. British Journal of Pharmacology. doi:10.1038/sj.bjp.0706414 bron
  889. Thomas TF, Metaxas ES, Nguyen T, Bennett W, Skiendzielewski KV, Quinn DH, Scaletta AL (2022). Case report: Medical cannabis—warfarin drug-drug interaction. Journal of Cannabis Research 4:4. doi:10.1186/s42238-021-00112-x bron
  890. Thompson GR 3rd, Tuscano JM, Dennis M, et al. (2017). A microbiome assessment of medical marijuana. Clinical Microbiology and Infection. doi:10.1016/j.cmi.2016.12.001 bron
  891. Thurgur H, et al. (2024). Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. British Journal of Clinical Pharmacology. doi:10.1111/bcp.15988 bron
  892. Tolon RM, Nunez E, Pazos MR, Benito C, Castillo AI, Martinez-Orgado JA, Romero J (2015). Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. Neurobiology of Aging 36(12):3179-3192. doi:10.1016/j.neurobiolaging.2015.08.020 bron
  893. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ (2006). Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. Journal of Glaucoma 15(5):349-353. doi:10.1097/01.ijg.0000212260.04488.60 bron
  894. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21. bron
  895. Transnational Institute (2020). Rescheduling cannabis at the UN level. Transnational Institute. bron
  896. Transnational Institute (2023). The UN Drug Control Conventions. Transnational Institute. bron
  897. Transport Online (2025). Chauffeur volgens rechter onterecht op staande voet ontslagen na positieve speekseltest op cannabis. transport-online.nl. bron
  898. Transvaal Bereidingsapotheek (2025). Medicinale cannabisolie: recept, kosten en levering. transvaalapotheek.nl. bron
  899. Transvaal Bereidingsapotheek (2024). Bijsluiter medicinale cannabisolie. transvaalapotheek.nl. bron
  900. Transvaal Bereidingsapotheek (2026). Wat kost medicinale cannabis?. transvaalapotheek.nl. bron
  901. Transvaal Bereidingsapotheek (2024). Informatie voor arts en apotheker - medicinale cannabis. transvaalapotheek.nl. bron
  902. Transvaal Bereidingsapotheek (2024). Veelgestelde vragen Cannabisolie (voor professionals). transvaalapotheek.nl. bron
  903. Trimbos-instituut (2024). Cannabis (hasj en wiet) - informatie. Drugsinfo.nl. bron
  904. Trimbos-instituut (2024). ICan:minder blowen — interventie voor stoppen en minderen met cannabis. Trimbos-instituut (trimbos.nl). bron
  905. Trimbos-instituut (2023). Factsheet Cannabispreventie. trimbos.nl. bron
  906. Trimbos-instituut (2024). Alcohol-, drugs- en medicijnbeleid (ADM-beleid). trimbos.nl. bron
  907. Trimbos-instituut (2023). Problematisch cannabisgebruik: cijfers en preventie. Trimbos-instituut. bron
  908. Trimbos-instituut (2024). Wat mensen niet weten als ze cannabis eten. trimbos.nl. bron
  909. Trimbos-instituut (z.j.). Cannabis en zwangerschap. Drugsinfo.nl. bron
  910. Trimbos-instituut (2025). Cannabis (informatiemiddel drugs): THC-gehalte, risico's en risicogroepen. Trimbos-instituut. bron
  911. Trimbos-instituut (2023). Nieuw wetsvoorstel voor nieuwe psychoactieve stoffen: een effectief verbod?. trimbos.nl. bron
  912. Trimbos-instituut (2025). Alcohol- en drugstesten op het werk en de wet. trimbos.nl. bron
  913. Trimbos-instituut (2023). CBD-gehalte in cannabis niet zo belangrijk als gedacht. Trimbos-instituut. bron
  914. Trimbos-instituut (2025). THC-monitor: hoe sterk zijn wiet en hasj?. trimbos.nl. bron
  915. Trimbos-instituut (2024). Drugsgebruik onder volwassenen in Nederland in 2024: stijging stimulerende middelen. trimbos.nl. bron
  916. Trimbos-instituut (2024). Factsheet Cannabispreventie. Trimbos-instituut. bron
  917. Trimbos-instituut (Drugs Infolijn) (actueel). De gevolgen van blowen op jonge leeftijd. Drugsinfo.nl (Trimbos-instituut). bron
  918. Trimbos-instituut (Drugsinfo.nl) (2026). Wat is HHC? Werking, risico's en juridische status. Drugsinfo.nl. bron
  919. Trimbos-instituut (DrugsInfo.nl) (2024). Hasj/wiet & Diabetes Medicatie. DrugsInfo.nl. bron
  920. Trimbos-instituut (Drugsinfo) (2026). Wat is THC?. drugsinfo.nl. bron
  921. Trimbos-instituut (Expertisecentrum Alcohol) (2024). Risico's van combinatiegebruik. Trimbos.nl. bron
  922. Trimbos-instituut (in opdracht van het WODC) (2025). Lood en pesticiden aangetroffen in cannabis uit Nederlandse coffeeshops. Trimbos-instituut. bron
  923. Trimbos-instituut (in opdracht van WODC, Ministerie van Justitie en Veiligheid) (2025). Onderzoek Experiment Gesloten Coffeeshopketen — rapportage nulmeting contaminantenanalyse. WODC / Rijksoverheid. bron
  924. Trimbos-instituut / Nationale Drug Monitor (2025). Cannabis en mentale gezondheid; THC-gehalte nederwiet. nationaledrugmonitor.nl. bron
  925. Trimbos-instituut / WODC (Nationale Drug Monitor) (2025). NPS-wetgeving (paragraaf 2.1.2). Nationale Drug Monitor. bron
  926. Trimbos-instituut, Nationale Drug Monitor (2025). Cannabis - Over cannabis. nationaledrugmonitor.nl. bron
  927. Tsuda Y, Saruwatari J, Yasui-Furukori N (2014). Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. bron
  928. Tuchtcolleges voor de Gezondheidszorg (2024). Tuchtcolleges voor de Gezondheidszorg. tuchtcollege-gezondheidszorg.nl. bron
  929. Tudge L, Williams C, Cowen PJ, McCabe C (2015). Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers. International Journal of Neuropsychopharmacology. doi:10.1093/ijnp/pyu094 bron
  930. Turcotte C, Blanchet MR, Laviolette M, Flamand N (2016). The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences. doi:10.1007/s00018-016-2300-4 bron
  931. Turner AR, Spurling BC, Agrawal S (2023). Marijuana Toxicity. StatPearls [Internet], NCBI Bookshelf. bron
  932. Tweede Kamer der Staten-Generaal (2022). Wijziging Opiumwet i.v.m. CBD - memorie van toelichting (Kamerstuk 36159, nr. 3). officielebekendmakingen.nl. bron
  933. Twelves C, Sabel M, Checketts D, et al. (2021). A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer, 124:1379-1387. doi:10.1038/s41416-021-01259-3 bron
  934. Twelves C, Sabel M, Checketts D, Miller S, Tayo B, Jove M, Brazil L, Short SC, McBain C, Haylock B, Mulholland P, Herbert C, James A, Hingorani M, Berrouschot J, Fietkau R, Panse J (2021). A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer. doi:10.1038/s41416-021-01259-3 bron
  935. Twelves C, Short SC, Mulholland P, et al. (2024). A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer. doi:10.1186/s12885-023-11792-4 bron
  936. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB, Yoshimura N, Tyagi P (2009). Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. Journal of Urology. doi:10.1016/j.juro.2008.11.078 bron
  937. U.S. Anti-Doping Agency (USADA) (2026). Marijuana FAQ. usada.org. bron
  938. U.S. Customs and Border Protection (2024). CBP Reminds Travelers from Canada that Marijuana Remains Illegal in the United States. cbp.gov. bron
  939. U.S. Department of Veterans Affairs & Department of Defense (Schnurr PP, et al.) (2023). The Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Synopsis of the 2023 VA/DoD Clinical Practice Guideline. Annals of Internal Medicine. doi:10.7326/M23-2757 bron
  940. U.S. Embassy & Consulates in Canada (2023). Cannabis and the U.S.-Canada Border. ca.usembassy.gov. bron
  941. U.S. Food and Drug Administration (2024). EPIDIOLEX (cannabidiol) oral solution - Full Prescribing Information. FDA Drug Label (accessdata.fda.gov). bron
  942. U.S. Food and Drug Administration (2022). 5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC. FDA Consumer Updates. bron
  943. U.S. Food and Drug Administration (2022). FDA Warns Consumers About the Accidental Ingestion by Children of Food Products Containing THC. FDA.gov. bron
  944. U.S. Food and Drug Administration (2023). Warning Letters for Cannabis-Derived Products. fda.gov. bron
  945. U.S. Food and Drug Administration (FDA) (2019). Hemp Production and the 2018 Farm Bill. U.S. Food and Drug Administration. bron
  946. U.S. Food and Drug Administration (FDA) (2024). EPIDIOLEX (cannabidiol) oral solution — Prescribing Information (2024). FDA accessdata (NDA 210365s021). bron
  947. U.S. Food and Drug Administration / Jazz Pharmaceuticals (2025). EPIDIOLEX (cannabidiol) oral solution - Prescribing Information. FDA Drugs@FDA label. bron
  948. U.S. Food and Drug Administration / NeurologyLive (2018). FDA Approves Cannabidiol (Epidiolex) for Lennox-Gastaut and Dravet Syndromes. NeurologyLive. bron
  949. Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. (2019). Cannabichromene is a cannabinoid CB2 receptor agonist. British Journal of Pharmacology. doi:10.1111/bph.14815 bron
  950. UN News (2020). UN commission reclassifies cannabis, yet still considered harmful. UN News. bron
  951. Universiteit Utrecht, Faculteit Diergeneeskunde (Joris Robben, NVIC) (2019). Hond Jaymes werd vergiftigd door drugs: wat moet je dan doen?. Universiteit Utrecht / Nationaal Vergiftigingen Informatie Centrum. bron
  952. UNODC (2020). CND Votes on Recommendations for Cannabis and Cannabis-Related Substances. UNODC Frontpage. bron
  953. UNODC / Commission on Narcotic Drugs (2025). CND decision on international control of hexahydrocannabinol (HHC) and carisoprodol enters into force. UNODC Laboratory and Scientific Service - Announcements. bron
  954. Urbi B, Corbett J, Hughes I, Owusu MA, Thorning S, Broadley SA, Sabet A, Heshmat S (2022). Effects of Cannabis in Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease. doi:10.3233/JPD-212923 bron
  955. Vaid R, Fareed A, Qader R, et al. (2025). Cannabis use in Crohn's disease: a systematic review and meta-analysis of randomized controlled trials (RCTs). Irish Journal of Medical Science. doi:10.1007/s11845-024-03844-w bron
  956. van Breemen RB, Muchiri RN, Bates TA, Weinstein JB, Leier HC, Farley S, Tafesse FG (2022). Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. Journal of Natural Products. doi:10.1021/acs.jnatprod.1c00946 bron
  957. van Dam CJ, van der Schrier R, van Velzen M, Dahan A, et al. (2023). Inhaled Δ9-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers. British Journal of Anaesthesia. doi:10.1016/j.bja.2022.10.020 bron
  958. van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M (2019). An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. doi:10.1097/j.pain.0000000000001464 bron
  959. van den Elsen GAH, Ahmed AIA, Lammers M, et al. (2014). Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Research Reviews. doi:10.1016/j.arr.2014.01.007 bron
  960. van den Elsen GAH, Ahmed AIA, Verkes RJ, et al. (2015). Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. doi:10.1212/WNL.0000000000001675 bron
  961. Van der Gouwe D, Ehrlich E, Van Laar MW (Trimbos-instituut) (2009). Het drugsbeleid in Nederland. Trimbos-instituut. bron
  962. van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, et al. (2017). Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science 356(6342):1084-1087. doi:10.1126/science.aaf7497 bron
  963. Van Stuijvenberg MP, Ramaekers GMGI, Bijpost Y (2011). Cannabinoïd-hyperemesis-syndroom. Nederlands Tijdschrift voor Geneeskunde. bron
  964. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ (2017). Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. Journal of Analytical Toxicology. doi:10.1093/jat/bkx012 bron
  965. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO (2015). Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products. JAMA. doi:10.1001/jama.2015.6613 bron
  966. Various (PMC review) (2024). Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol. PMC / peer-reviewed review. bron
  967. Vaughn SE, Strawn JR, et al. (2022). Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient. Journal of Personalized Medicine / PMC. bron
  968. Vaughn SE, Strawn JR, Poweleit EA, Sarangdhar M, Ramsey LB (2021). The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. Journal of Personalized Medicine. doi:10.3390/jpm11070615 bron
  969. Venhuis BJ, van de Nobelen S (2015). Cannabis contaminanten. RIVM Rapport 2015-0205. bron
  970. Verbond van Verzekeraars (2023). Protocol Verzekeringskeuringen. verzekeraars.nl. bron
  971. Verduijn MM, Hooymans CDM (2018). NHG-Standpunt Cannabis. Huisarts en Wetenschap 61(6):55-57. doi:10.1007/s12445-018-0138-8 bron
  972. Verenigde Naties (1961). Enkelvoudig Verdrag inzake verdovende middelen, 1961, zoals gewijzigd door het Protocol tot wijziging van het Enkelvoudige Verdrag inzake verdovende middelen, 1961. wetten.overheid.nl. bron
  973. Vermersch P, et al. (2023). Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials. PubMed (CNS Drugs). bron
  974. Villanueva MRB, et al. (2023). Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review. Pain Management Nursing. bron
  975. Viveiros MMH, et al. (2022). Anti-inflammatory effects of α-humulene and β-caryophyllene on pterygium fibroblasts. International Journal of Ophthalmology. bron
  976. VMT (vakblad voedingsmiddelenindustrie) (2020). CBD als levensmiddel: geen drug, of soms toch wel? De interactie tussen levensmiddelen- en opiumwetgeving. vmt.nl. bron
  977. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry. doi:10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D bron
  978. Wade DT, Collin C, Stott C, Duncombe P (2010). Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Multiple Sclerosis Journal 16(6):707-714. bron
  979. Walitt B, Klose P, Fitzcharles MA, Phillips T, Hauser W (2016). Cannabinoids for fibromyalgia. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD011694.pub2 bron
  980. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH (2015). Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. The Journal of Pain. bron
  981. Wang L, Hong PJ, May C, et al. (2021). Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. doi:10.1136/bmj.n1034 bron
  982. Wang M, Wang YH, Avula B, Radwan MM, Wanas AS, van Antwerp J, Parcher JF, ElSohly MA, Khan IA (2016). Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis and Cannabinoid Research. doi:10.1089/can.2016.0020 bron
  983. Wang Y, Robinson KR, et al. (2023). Medical Cannabis Use and Its Impact on Health Among Older Adults. Current Addiction Reports. doi:10.1007/s40429-023-00519-x bron
  984. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP (2010). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182(14):E694–E701. doi:10.1503/cmaj.091414 bron
  985. Wąsik J, Likońska A, Kurowski M (2024). IgE-Mediated Allergy and Asymptomatic Sensitization to Cannabis Allergens—Review of Current Knowledge and Presentation of Six Cases. Medicina (Kaunas). doi:10.3390/medicina60060954 bron
  986. Wasserstein RL, Lazar NA (American Statistical Association) (2016). The ASA Statement on p-Values: Context, Process, and Purpose. The American Statistician. doi:10.1080/00031305.2016.1154108 bron
  987. Watts S, McElroy M, Migicovsky Z, Maassen H, van Velzen R, Myles S (2021). Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants. doi:10.1038/s41477-021-01003-y bron
  988. Weber M, Goldman B, Truniger S (2010). Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. Journal of Neurology, Neurosurgery & Psychiatry. doi:10.1136/jnnp.2009.192583 bron
  989. Weinstock A, et al. (2024). Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program. Epilepsia Open. doi:10.1002/epi4.13013 bron
  990. Wenger JP, et al. (2020). Validating a predictive model of cannabinoid inheritance with feral, clinical, and industrial Cannabis sativa. American Journal of Botany. doi:10.1002/ajb2.1550 bron
  991. Werz O, Seegers J, Schaible AM, Weinigel C, Barz D, Koeberle A, Allegrone G, Pollastro F, Zampieri L, Grassi G, Appendino G (2014). Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. PharmaNutrition. doi:10.1016/j.phanu.2013.10.002 bron
  992. Westin AA, Mjønes G, Burchardt O, Fuskevåg OM, Slørdal L (2014). Can Physical Exercise or Food Deprivation Cause Release of Fat-Stored Cannabinoids?. Basic & Clinical Pharmacology & Toxicology. doi:10.1111/bcpt.12235 bron
  993. Weston-Green K, Clunas H, Jimenez Naranjo C (2021). A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. Frontiers in Psychiatry 12:583211. doi:10.3389/fpsyt.2021.583211 bron
  994. White MA, Burns NR (2023). Does the co-use of cannabis exacerbate the effect of alcohol on the risk of crashing? A systematic review and meta-analysis. Drug Science, Policy and Law. doi:10.1177/20503245231177334 bron
  995. Whiting PF, Wolff RF, Deshpande S, et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. doi:10.1001/jama.2015.6358 bron
  996. Wikipedia contributors (2024). Nabiximols (Sativex). Wikipedia. bron
  997. Wikipedia contributors (2026). Cannabis in Turkey. Wikipedia. bron
  998. Wikipedia contributors (2026). Cannabis in the United Arab Emirates. Wikipedia. bron
  999. Wikipedia contributors (2026). Cannabis drug testing. Wikipedia. bron
  1000. Wikipedia contributors (2026). Legality of cannabis. Wikipedia. bron
  1001. Wikipedia contributors (2024). Single Convention on Narcotic Drugs. Wikipedia. bron
  1002. Wilson JK, Freeman TP et al. (2026). The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry. doi:10.1016/S2215-0366(26)00015-5 bron
  1003. Wilson KM, Torok MR, Wei B, et al. (2017). Health effects of exposure to second- and third-hand marijuana smoke: a systematic review. CMAJ Open. doi:10.9778/cmajo.20170112 bron
  1004. Wise LA, Wang TR, Willis SK, Wesselink AK, Rothman KJ, Mikkelsen EM (2021). Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss. Human Reproduction 36(5):1405-1415. bron
  1005. Woelk H, Schläfke S (2010). A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to lorazepam for generalized anxiety disorder. Phytomedicine 17(2):94-99. doi:10.1016/j.phymed.2009.10.006 bron
  1006. Wolfe D, Corace K, Butler C, et al. (2023). Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature. PLoS One. doi:10.1371/journal.pone.0281826 bron
  1007. Wong A, Montebello ME, Norberg MM, et al. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2013.07.031 bron
  1008. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR (2011). Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. doi:10.1053/j.gastro.2011.07.036 bron
  1009. Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, Burton D, Zinsmeister AR (2012). Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterology & Motility. doi:10.1111/j.1365-2982.2011.01874.x bron
  1010. Workman CD, Fietsam AC, Sosnoff J, Rudroff T (2021). Increased Likelihood of Falling in Older Cannabis Users vs. Non-Users. Brain Sciences 11(2):134. doi:10.3390/brainsci11020134 bron
  1011. Workman CD, Fietsam AC, Sosnoff J, Rudroff T (2021). Increased Likelihood of Falling in Older Cannabis Users vs. Non-Users. Brain Sciences. doi:10.3390/brainsci11020134 bron
  1012. World Anti-Doping Agency (WADA) (2026). WADA's 2026 Prohibited List is now in force. wada-ama.org. bron
  1013. World Health Organization (2025). UN Commission approves WHO recommendations to place psychoactive substances under international control. WHO News (13-03-2025). bron
  1014. World Health Organization, Expert Committee on Drug Dependence (ECDD) (2018). Cannabidiol (CBD): Critical Review Report. WHO Expert Committee on Drug Dependence, 40th Meeting, Geneva. bron
  1015. Wright S, et al. (2012). Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex) in people with multiple sclerosis: a new approach. Trials. doi:10.1186/1745-6215-13-189 bron
  1016. Yimer B, et al. (2024). The relationship between cannabis and nicotine use: A systematic review and meta-analysis. Addiction. doi:10.1111/add.16642 bron
  1017. Zagzoog A, Halter K, Jones AM, Bannatyne N, Cline J, Wilcox A, Smolyakova A-M, Laprairie RB (2024). The Intoxication Equivalency of 11-Hydroxy-delta9-Tetrahydrocannabinol Relative to delta9-Tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics. doi:10.1124/jpet.123.001998 bron
  1018. Zhang N, Woldeamanuel YW (2021). Medication overuse headache in patients with chronic migraine using cannabis: a case-referent study. Headache: The Journal of Head and Face Pain. doi:10.1111/head.14195 bron
  1019. Zheng Y, Reid P, Smith PF (2015). Cannabinoid CB1 Receptor Agonists Do Not Decrease, but may Increase Acoustic Trauma-Induced Tinnitus in Rats. Frontiers in Neurology. doi:10.3389/fneur.2015.00060 bron
  1020. Zimmermann S, Reinhard I, Koopmann A, et al. (2025). Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial. Molecular Psychiatry. doi:10.1038/s41380-024-02869-y bron
  1021. Zoll (German Customs) (2024). Medicinal products and narcotics — Travel within the EU. zoll.de. bron
  1022. ZonMw (2020). Verkenning medicinale cannabis. ZonMw / Rijksoverheid. bron
  1023. Zorginstituut Nederland (2024). Serotonineheropnameremmers, selectief (SSRI's) — groepstekst. Farmacotherapeutisch Kompas. bron
  1024. Zorginstituut Nederland (2025). Opioïden (groepstekst). Farmacotherapeutisch Kompas. bron
  1025. Zorginstituut Nederland (2022). GVS-advies cannabidiol (Epidyolex®) als aanvullende behandeling bij 2 ernstige epileptische aandoeningen. zorginstituutnederland.nl. bron
  1026. Zorginstituut Nederland (2017). Herbeoordeling medicinale cannabis: geen verzekerde zorg. Zorginstituut Nederland. bron
  1027. Zorginstituut Nederland (2025). GVS-advies: vergoed cannabidiol (Epidyolex) voor de behandeling van de ziekte van Bourneville-Pringle (tubereuze sclerose complex). Zorginstituut Nederland. bron
  1028. Zorginstituut Nederland (2017). Medicinale cannabis niet in basispakket. Zorginstituut Nederland. bron
  1029. Zorginstituut Nederland (2022). Zorginstituut adviseert om medicijn cannabidiol te vergoeden voor kinderen met ernstige epilepsie. Zorginstituut Nederland (nieuws). bron
  1030. Zorginstituut Nederland (Farmacotherapeutisch Kompas) (2026). Cannabidiol - preparaattekst en interacties. Farmacotherapeutisch Kompas. bron
  1031. Zou S, Kumar U (2016). Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Frontiers in Cellular Neuroscience. doi:10.3389/fncel.2016.00294 bron
  1032. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P (2002). Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. International Clinical Psychopharmacology. bron
  1033. Zwiebel H, Greenky D, Goldman RD (2025). Accidental cannabis ingestion in young children. Canadian Family Physician 2025;71(3):161-163. doi:10.46747/cfp.7103161 bron